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ABSTRACT
Numerous studies have demonstrated that many nutraceuticals have potential
capacity to mitigate the symptoms of aging and age-related disorders. We found that
Royal Jelly (RJ/eRJ) consumption could extend C. elegans lifespan and increase stress
tolerance in an IIS/DAF-16 dependent manner. In consideration that the transactivity of
DAF-16 is tightly controlled by its co-factors, our further results indicated that SIR-2.1,
14-3-3, and HCF-1 could interact with each other to fine-tune the activity of DAF-16.
Additionally, these co-factors were also required in RJ/eRJ mediated stress tolerance.
Given that aging is characterized with progressively declined physiological
functions, it is intriguing to investigate whether RJ/eRJ supplementation could slow down
the development of neurodegenerative diseases. Strikingly, our results showed that
RJ/eRJ supplementation delayed the β-amyloid (Aβ)-toxicity induced body paralysis in C.
elegans AD model. The genetic analysis indicated that the RJ/eRJ mediated Aβ toxicity
alleviation required Insulin/IGF Signaling (IIS) pathway and DAF-16, rather than HSF-1
and SKN-1. Further research found that RJ/eRJ relied on DAF-16 to significantly
improve the protein solubility in aged worms, which implied that RJ/eRJ supplementation
promoted proteostasis and reduced proteotoxicity in AD worms. Additionally, RJ/eRJ
also increased the solubility of Aβ species. In considering that RJ/eRJ supplementation
slowed down the Aβ-induced paralysis in C. elegans, it is possible that RJ/eRJ mediated
protection against Aβ toxicity might be dependent on increasing the solubility of Aβ
species.
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Overall, our findings revealed that the anti-aging function of RJ/eRJ
supplementation and underscored the relationship between the improved proteostasis and
the prevention of neurodegenerative disorders.
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CHAPTER ONE : INTRODUCTION
1.1 Aging is genetically controlled

Aging, a process of becoming older, is a universal inevitable process associated
with declining physiological functions. Based on our knowledge, aging is characterized
by declining stress resistance, increased homeostatic imbalance, and elevated risk of
disease[1-3]. To date, the increase of aging population has been a big challenge in the
United States. Statistical data estimates that more than 20% of the population will be over
65 years old by 2030, and the cost of medical treatment for age-related diseases will be
tripled in 2050. This aging population growth could slow the nation’s economic growth
in the near future[4, 5]. Therefore, it is urgent for scientists to develop new therapeutic
treatments to delay aging and the onset of age-related disorders.
1.1.1 Aging is regulated through genetic pathways

Most biological processes, if not all, are controlled by genes, and aging follows
the same rule. It is genetically controlled by an elaborate genetic network[6-8].
Numerous publications showed that some conserved genetic pathways regulate longevity
and prevent the age related disorders (Figure 1.1). Dietary interventions and genetic
alterations could manipulate genes and pathways to play an important role in the aging
process[9-11].
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Figure 1.1 Conserved nutrient signaling pathways regulating longevity. (Fontana et
al., 2010)
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1.1.1.1 Model Organisms are utilized to study the molecular mechanism of aging

Model organisms that mimic human responses provide us with a good platform to
investigate the detailed molecular mechanism of diseases[12, 13]. Moreover, these classic
model organisms offer numerous opportunities to evaluate the efficiency of drugs and
therapeutic treatments[14, 15]. The well-established models in the research of aging
including the yeast Saccharomyces cerevisiae, nematode Caenorhabditis elegans, fruit
fly Drosophila melanogaster, hydra, zebrafish, and many rodents, which were crucial in
identifying the conserved pathways that regulate human aging[16-18]. In our research,
roundworm Caenorhabditis elegans (C. elegans) was utilized as an animal model to
investigate the molecular mechanism of aging and age-related disorders.
C. elegans is a free-living transparent multicellular animal simple enough to study
the details of genetic pathways. C. elegans is considered a powerful model for studying
aging due to its numerous advantages in culturing and genetic analysis[19, 20]. For
instance, C. elegans is easy to culture to a bulk population, and it takes three days for the
development of one generation and three weeks for the total lifespan. Moreover, these
transparent animals can be used in high throughput automated experiments, which makes
them an ideal tool to study the genetic regulation of aging[21]. Comparison of C. elegans
and human genomes confirmed that nearly 80% of human disease genes and pathways
are present in C. elegans, which indicates that C. elegans is a good model to study human
disease[22-24]. However, the simple structure of C. elegans places some limitations for
modeling human aging. They are multicellular organisms lacking tissues and organs, and
therefore unable to regenerate their tissues, which make them limited in serving as a
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model to study the aging of highly proliferative tissues[25-27]. Overall, although C.
elegans is a primitive and simple organism, it shares many fundamental molecular
structures and biological characteristics with more advanced organisms[12, 28].
1.1.1.2 Insulin/IGF Signaling (IIS) pathway and DAF-16

Insulin/IGF Signaling (IIS) pathway is the most powerful pathways for regulating
longevity and is highly conserved from C. elegans to human beings[29, 30]. In response
to insulin-like peptides (ILPs), the transmembrane receptor DAF-2 (Insulin/IGF-1)
triggers the activation of many protein kinases, including AGE-1/PI3K and AKT/PKB,
which leads to phosphorylation and subsequent cytoplasmic retention of the main
downstream effector DAF-16/FOXO (Figure 1.2). However, in some special conditions,
such as low nutrients or starving, this pathway is inactivated and thereby DAF-16 is
unphophorylated. Without phosphorylation, DAF-16 translocates from cytosol to nucleus
and, in turn, elevates expression level of its target genes[31, 32]. These DAF-16
downstream genes have many essential biological functions, such as promoting stress
tolerance, altering metabolic and development responses, improving immunity, and
extending lifespan[33-35].
In addition to DAF-16, heat shock factor 1 (HSF-1) and SKN-1 are two other
critical transcriptional factors of the IIS pathway[32]. Specifically, HSF-1 regulates a
series of heat shock proteins (HSPs) under stress conditions[36, 37]. HSF-1 is
phosphorylated and inactive under normal condition; upon thermal stress, HSF-1 is
released and translocated to the nucleus. As a result, HSF-1 induces the expression of
HSPs to protect the proteome from destruction. It has been proposed that HSF-1 plays a
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key role in lifespan extension and prevention of proteopathy, diseases caused by aberrant
protein structure[38, 39]. The third transcriptional factor is SKN-1, which is also located
at the downstream of IIS pathway and parallel to DAF-16 and HSF-1. Noticeably, SKN-1
plays a very important role in anti-oxidative stress and metal detoxification[40, 41].
Although DAF-16, HSF-1, and SKN-1 have different biological functions and are
parallel to each other, they mutually interact and some of their target genes are
overlapping [38, 42, 43].
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Figure 1.2 The Insulin/IGF Signaling Pathway and DAF-16/FOXO. (Nemoto et al.,
2004)
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1.1.1.3 Important co-factors of DAF-16

Numerous studies have indicated that the precise control of DAF-16
transcriptional activity is a key regulatory step for longevity determination[44]. DAF-16
activity is regulated by post-translational modifications, nuclear/cytoplasmic
translocation, and association with transcriptional co-regulators. Although necessary for
its activation, translocation of DAF-16 into the nucleus is not sufficient to stimulate its
transcriptional activity[45, 46]. Association with additional co-factors is also necessary
for nuclear DAF-16 activation [44, 47]. It has been proposed that SIR-2.1, HCF-1 and 143-3 are important co-factors (binding partners) of DAF-16[3, 48, 49].
SIR-2.1, the C. elegans homolog of the yeast NAD+-dependent protein
deacetylase, plays an important role in stress response and calorie restriction mediated
lifespan extension[50, 51]. As an important co-factor of DAF-16, SIR-2.1 is thought to
activate DAF-16 in conferring longevity as well as stress resistance. It is reported that in
mammals, SIRT1(homolog of C. elegans SIR-2.1) can bind to and deacetylate forkhead
proteins, which in turn influences the transactivity of FOXOs and thereby increases the
resistance of mammalian cells to oxidative-damage induced apoptosis[52-54]. Numerous
studies also demonstrated that the overexpression of SIR2 homologs in worms, yeast and
flies extends lifespan, emphasizing the evolutionarily conserved role of SIR2 in longevity
determination[54, 55]. Noticeably, recent studies revealed that heat stress stimulates the
physical association of SIR-2.1 with DAF-16 via the scaffolding protein 14-3-3, which
promotes the transactivation of DAF-16[48]. This finding indicated that SIR-2,1 could
interact with other proteins to activate DAF-16.
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14-3-3 proteins, also co-factors for DAF-16, function as docking proteins to
bridge DAF-16 with other important co-factors. 14-3-3 proteins are small acid proteins,
which could bind to diverse groups of signaling molecules to participate in a wide variety
of cellular processes, including cell cycle checkpoints, DNA repair, cell differentiation
and cell apoptosis[56, 57]. By binding to proteins, 14-3-3 proteins can induce the
conformational change of the substrate proteins, sequester the substrates in the cytoplasm,
or act as a scaffold that bridges two interacting partners as with DAF-16 and its cofactors[58, 59].
In C. elegans, there are two 14-3-3 proteins: PAR-5/FTT-1 and FTT-2. PAR-5 is
required for cellular asymmetry in the early C. elegans embryo[60, 61]. FTT-2 sequesters
DAF-16 in the cytosol by forming a protein complex, which in turn inactivates DAF16[62]. Between these two 14-3-3 proteins, only FTT-2 could affect dauer formation,
DAF-16 localization, and transcriptional activates; PAR-5 does not have this function[3,
62].
Counter to these DAF-16 activation co-factors, the DAF-16 co-repressors downregulate DAF-16’s transactivity. Host Cell Factor-1 (HCF-1) belongs to a family of
highly conserved HCF proteins and acts as a nuclear co-repressor of DAF-16. The main
role of HCF-1 is to help fine tune the regulation of a subset of DAF-16 downstream genes
to modulate survival under specific conditions. By regulating the function of DAF-16,
HCF-1 is essential for longevity maintenance in C. elegans[49].
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In mammal studies, HCF-1 was reported to play a key role in cell cycle
progression at the G1/S transition, M phase, and cytokinesis. In its diverse biological
roles, mammalian HCF-1 acts by binding to and regulating many different transcriptional
and chromatin factors and assembling appropriate protein complexes for contextdependent gene regulation. In C.elegans, HCF-1 mutant exhibits declined reproductive
ability and low penetrance of embryonic lethality, both phenotypes consistent with a role
of HCF-1 in cell proliferation[63, 64]. Similar to the results found in mammalian research,
HCF-1 in C. elegans also functions in proper cell cycle maintenance and cell
proliferation[65]. Interestingly, Li et al reported that HCF-1 is also a critical longevity
determinant and transcriptional regulator of DAF-16, which is necessary for maintaining
normal lifespan and stress response in C. elegans[49, 66]. In the absence of hcf-1, more
DAF-16 was released and localized to the nucleus and significantly up-regulated the
expression of DAF-16 target genes. This up-regulation of DAF-16 indicates that HCF-1
modulates C.elegans lifespan and stress response by acting as a negative regulator of
DAF-16. Furthermore, Riziki et al. reported that HCF-1 could also interact with SKN-1
in stress response. Although HCF-1 is not regulated by IIS pathway, it still functions as
an important factor to modulate downstream components of IIS pathway[67].
To date, a growing body of evidence indicates that DAF-16’s co-factors
physically interact with each other to regulate DAF-16’s activity[48, 68, 69]. For instance,
in mammalian cells, HCF-1 affects the expression of several SIRT1/FOXO
transcriptional targets and physically associates with both FOXO3 and SIRT1[65]. This
interaction also exists in C. elegans genetic regulation. In C. elegans, SIR-2.1 forms a

9

protein complex with DAF-16 and requires DAF-16 activity to modulate lifespan. The
protein complex of DAF-16 and SIR-2.1 forms in the nucleus and requires 14-3-3
proteins as bridging molecules. Moreover, 14-3-3 proteins also physically associate with
HCF-1. Based on genetic analyses, it is known that SIR-2.1 functions upstream of HCF-1,
and both HCF-1 and SIR-2.1 functions upstream of DAF-16. Taken together, given
certain signals, the activity of DAF-16 is regulated via the interplays between SIR-2.1,
HCF-1 and 14-3-3 proteins.
1.1.1.4 Other longevity-related pathways

In addition to IIS pathway, other pathways, such as JNK, P38 MAPK, and TOR
pathways, are also reported as critical modulators in aging and age-related diseases.
Numerous evidence showed that some crossover molecules among these pathways
contribute to form a complex genetic network to regulate longevity as well as other
important biological processes (Figure 1.1) [70-73].
C-Jun N-terminal kinase (JNK) pathway has been implicated in critical biological
processes such as cell development, survival, apoptosis, and cancer. The JNK family, a
subgroup of the mitogen-activated protein kinase superfamily, is part of a signal
transduction cascade that is activated by cytokines and external stresses, such as
oxidative stress and heat shock stress[73, 74]. To date, it has been proposed that JNK
pathway functions at the center of a signal transduction network that coordinates the
induction of protective genes in response to oxidative stress, which can reduce the toxic
effects of reactive oxygen species (ROS)[75, 76]. Moreover, under the heat shock stress,
JNK-1 (an important component of JNK pathway) directly interacts and phosphorylates
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DAF-16 to promote DAF-16 translocation into nucleus, which in turn extends the
lifespan of C. elegans[77, 78].
P38 mitogen-activated protein kinase (P38 MAPK) pathway is composed of series
mitogen-activated protein kinases, which are activated by variety of cellular stresses such
as cytokines, ultraviolet irradiation, heat shock, and osmotic shock. It is also involved in
cell differentiation, apoptosis and autophagy[79, 80]. It is well known that p38 MAPK
signaling pathway works in cooperation with IIS pathway to regulate C.elegans’ immune
system in response to bacterial infection[80]. Dinh et al. reported that cranberry could
protect C. elegans against Vibrio cholerae infection by inducing IIS/HSF-1 and P38
MAPK signaling pathways[81].
TOR (target of rapamycin) pathway, which regulates autophagy of proteins and
lipids in response to nutrition levels, is also involved in longevity regulation. Reduced
TOR signaling causes reduction in caloric intake without accompanying malnutrition,
which leading to further longevity benefits. It is reported that a TOR pathway inhibitor,
rapamycin, has been shown to extend lifespan in murine model[82, 83]. This finding
further confirmed the lifespan extension function of TOR pathway. In addition to
longevity, TOR pathway also controls several cellular processes including translation
initiation and elongation, autophagy, mitochondrial respiration, and induction of stress
response pathways[84-86].
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1.1.2 Dietary intervention is a feasible method to modulate longevity
1.1.2.1 Dietary intervention and nutrigenomics

Although dietary intervention and genetic alteration are two essential methods for
manipulating genes and pathways in the aging process, dietary intervention is more
feasible and efficient to promote healthy aging[87-89].
Nutraceutical supplementation is the most popular and well-studied dietary
intervention approach. A nutraceutical is defined as a product derived from food sources
possessing pharmaceutical functions in addition to their basic nutritional benefits[90, 91].
To date, a growing body of evidence demonstrates how nutraceutical supplementation
plays a key role in lifespan extension and alleviation of the symptoms of aging and
stress[92, 93].
Nutrigenomics is provided as a research tool to investigate how nutrients affect
metabolic pathways and homeostatic control and consequently how nutrients affect the
aging process and disease[94]. Nutraceuticals, by regulating genetic pathways, mediate
lifespan extension and stress resistance. For instance, Ginkgo Biloba extract (EGb761), a
traditional Chinese medicine derived from the fruit of maidenhair tree, was reported to
extend lifespan and increase tolerance of oxidative stress and thermal stress in worms and
rat models. Noticeably, this anti-aging effect is dependent on Ginkgo medicated
overexpression of HSP-16.2[95]. Resveratrol, a functional extraction from grape seeds,
was discovered as a SIR-2.1/SIRT1 activator, which delays the progression of
neurodegenerative diseases[96]. Cocoa and its derivatives, another functional food, could
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improve endothelial function and protect against cardiovascular disease in mammalian
studies[97]. Taken together, numerous studies indicated that nutraceutical
supplementation functions as a genetic regulator to improve a healthy aging. Additionally,
the nutrigenomic approach highlighted the relationship between dietary interventions and
pro-longevity, revealed the molecular mechanism of age-related disorders, and served as
an efficient tool to further investigate how to prevent the neurodegenerative disease. In a
current study, a nutrigenomic approach is being utilized to investigate the molecular
mechanism underlying Royal Jelly mediated anti-aging effects.
1.1.2.2 Royal Jelly’s beneficial effects

Royal Jelly (RJ), a bee product, is secreted from the hypopharyngeal gland and
mandibular gland of the worker honeybee. RJ plays a key role in the development of the
queen honeybee, and it is part of the diet of honeybee larvae[98].
It is reported that Royal Jelly has numerous pharmacological characteristics, such
as anti-bacterial, antioxidant, anti-fatigue, and wound-healing properties[99-101].
Moreover, several studies carried out using mammalian models revealed that Royal Jelly
could maintain the balance of sugar and lipid metabolism and protect the liver from virus
invasions[102]. A chemical composition analysis has shown that Royal Jelly consists
mainly of proteins, sugars, lipids, vitamins, and free amino acids. Based on the previous
studies, it has been proposed that the 10-HAD, royalisin and apisin are the major
components contributing to the above pharmacological functions[103].
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In modern diets, the use of Royal Jelly has significantly increased because of the
trend toward the use of healthy, organic, nutraceutical, functional foods, and dietary
supplements. Besides the merits of Royal Jelly’s beneficial functions mentioned above,
one phenomenon suggests that Royal Jelly also has the beneficial functions for anti-aging.
In the honeybee Apis mellifera, queens live and reproduce for 1-4 years, but hive workers,
which are derived from the same diploid genome, live for only 3 to 6 weeks. Queens are
fed throughout their lives with Royal Jelly, while worker bees are fed with Royal Jelly for
only a short period of time during their larval stages[98, 104]. Based on this phenomenon,
it is believed that Royal Jelly might provide anti-aging agents for queens.
The recently studies demonstrated that Royal Jelly may contain the pro-longevity
factors and its pro-longevity effects may depend on the insulin signaling pathway[105,
106]. However, the detailed mechanisms underlying the pro-longevity effects of royal
jelly are largely unknown. Our lab focuses on the aging intervention study, which
attempts to unveil the mechanism of royal jelly mediated lifespan extension. Furthermore,
we will also investigate the potential correlation of pro-longevity effects and the
prevention of age-related disorders by supplying royal jelly.
1.2 Pro-longevity is often associated with increased stress tolerances

Numerous studies supported that extended longevity is often correlated with
increased resistance against various stressors, such as oxidative stress, heat shock, UV
irradiation, osmosis stress and pathogen stress[107, 108].
1.2.1 Oxidative Stress
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Oxidative stress is engendered by an imbalance between the production of free
radicals and the biological system’s capacity to detoxify their harmful effects via
antioxidants. Free radicals are formed in mitochondria during cell metabolism under
normal conditions. As a scavenger, antioxidants could attack and neutralize free radicals
and, in turn, prevents the oxidative stress. However, under chronic stress conditions or in
aged cells, the effectiveness of antioxidant defenses is declined and the harmful free
radicals can accumulate. As a result, the production of peroxides and free radicals could
cause damage to all components of a cell, including proteins, lipids and DNA.
Additionally, considering some reactive oxidative species act as cellular messengers in
redox signaling, the accumulation of free radicals can disrupt the normal function of
several signaling pathways[109, 110].

In humans, oxidative stress is thought to be involved in the development of
several aging-disorders, such as cancer, Parkinson's disease, Alzheimer's disease,
atherosclerosis, heart failure, and myocardial infarction. However, reactive oxygen
species are not always harmful. In short-term oxidative stress, free radicals could be used
by the immune system as a way to attack and kill pathogens and thereby protect organism
from bacterial infections[111].

1.2.2 UV Irradiation

Ultraviolet (UV) irradiation is known to damage DNA through the formation of
cyclobutane pyrimidine dimers (CPDs) and 6-4-photoproducts (6-4 PPs). UV induced
DNA damage triggers cell cycle arrest and apoptosis[112].
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In somatic cells and tissues, the metabolism derived genotoxic agents and
environmental factors (UV light or sunlight and radiation) cause DNA damage, resulting
in alterations of DNA chemical structure, including a break in a strand of DNA, a base
missing from the backbone of DNA, and DNA cross-linkages. These accumulative
damages can give rise to mutations and cell death. In response to these negative effects, a
series of DNA repair systems are activated to protect genomic integrity[113]. Once cell
detects the DNA damage, the specific repair molecules could bind at or near the site of
damage to fix the DNA alterations.

Nucleotide excision repair (NER), a general DNA repair system in response to
UV-induced DNA damage, functions to preserve and faithfully transmit DNA to the next
generation in many organisms across life domains[114]. Upon detecting an irregularity in
DNA structure, NER pathway is activated to remove the abnormal DNA and synthesize
new base pairs to seal the nick, which in turn to play a key role in maintaining genome
integrity[114]. In humans, mutations in NER genes cause several UV sensitive hereditary
disorders. For example, cockayne syndrome (CS) patients, who have defects in
transcription coupled nucleotide excision repair (TC-NER), suffer neurodecelopmental
problems and premature aging. Similar evidence also showed in mice model, xeroderma
pigmentosum (XP), a disease caused by XPD mutation, showed many symptoms of
premature aging and extreme cancer proneness[115, 116].
In addition to NER pathways, certain pathways and molecules also participate in
DNA damage response and conserved in mammals and C. elegans to repair different
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types of DNA damages, such as BER (base excision repair), NHEJ (nonhomolgous endjoining), HR (homologous recombination), ICL (interstrand crosslink repair), and
mismatch repair[113].
Aging is often associated with the dysfunction of the body over time, and this
regressive physiological function is caused by declined cellular repair system and
accumulative cellular damages. Many studies have shown that high levels of DNA
oxidative damages were detected in aging cells and organisms, which might further
induce the late-onset neurodegenerative diseases. Several studies showed that some
nutraceuticals might protect organisms from DNA damages. For instance, Inoue and his
colleagues reported that Royal Jelly could extend the C3H/HeJ mice lifespan by reducing
the DNA oxidative damage[106]. This finding indicated that RJ might have the potential
to maintain genomic integrity in aged animals.
1.2.3 Heat Shock Stress

Heat shock stress is produced when an organism is shifted to a higher temperature
than the ideal body temperature for certain period of time. As a result, the sudden
increased temperature could cause cellular damage to proteins’ structure and function to a
certain degree. In response to this thermal stress, the heat shock factor (HSF-1) is
activated to dramatically up-regulate the expression of heat shock proteins (HSPs) to
recover the destructed proteins and thereby protect organisms from this disruption[117].

It is well known that heat shock proteins (HSPs) play a critical role in protein
folding, aggregation, and degradation. In addition to heat shock, upregulation of HSPs
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could also be triggered by a variety of environmental stress conditions, such as
inflammation, toxins (heavy metal, UV light, toxic chemicals, et al.), starvation, wound
healing, and tissue remodeling. In normal condition, HSPs function as molecular
chaperones to guide newly synthesized proteins folding in functional configuration and
deliver them to right place at the right time, which in turn control protein quality and
maintain the function of proteome[118]. Moreover, some HSPs could attach to proteins to
signal their degradation via proteasome, affect their activities, and alter their cellular
location. Noticeably, ubiquitin plays a key role in assisting aberrant proteins degradation,
which decreases the proteotoxicity in cells[119, 120].

Given that heat shock stress and aging condition are always associated with the
production of destructed proteins (unfolded and misfolded proteins), which are in an
urgent need to be refolded or degraded by HSPs to recover proteins’ function and thereby
maintain protein homeostasis[121]. The disruption of this process could cause age-related
disorders and proteopathy. Numerous studies revealed that some nutraceuticals could
protect organisms from thermal stress. For instance, cranberry could protect C. elegans
from heat shock stress by elevating the expression of HSPs[122]. Additionally, further
research demonstrated that cranberry also protected C. elegans from Aβ toxicity and
thereby delayed the development of Alzheimer’s disease[123].

1.2.4 Osmotic Stress

Osmotic stress is caused by a sudden change in the solute concentration around a
cell, causing a rapid change in the movement of water across its cell membrane. Under
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conditions of high concentrations of salt, water is drawn out of the cells through osmosis.
This also inhibits the transport of substrates and cofactors into the cell thus “shocking”
the cell[124].

All organisms have mechanisms to respond to osmotic shock, with sensors and
signal transduction networks providing information to the cell about the osmolarity of its
surroundings, which activates responses to deal with extreme conditions. OSR-1
regulates survival under osmotic stress via UNC-43 and a conserved P38 MAP kinase
signaling cascade and likely regulating osmotic avoidance and resistance to acute
dehydration by distinct mechanisms. OSR-1 plays a central role in integrating stress
detection and adaptation responses by invoking multiple signaling pathways to promote
survival under hyperosmotic environments[125]. Current research also suggests that
osmotic stress in cells and tissues may significantly contribute to inducing many human
diseases[126].

1.3 Age-related disorders
1.3.1 Neurodegenerative diseases

Aging is one of the greatest risk factors to cause age-related disorders, and
neurodegenerative disease is the most common one in the aging population[127].
Neurodegenerative disease represents a series of diseases relative to the progressive loss
of neurons’ structure or function, including ASL (amyotrophic lateral sclerosis),
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Parkinson’s disease, Alzheimer’s disease, and Huntington disease. These diseases are
incurable, resulting in progressive neuron cells degeneration and death[128].

Sarcopenia is the age-related loss of the muscle mass and strength, which cause
functional limitations in daily living, frailty and disabilities, and finally a higher mortality
rate in the elderly patients. Given that satellite cells are resident myogenic progenitors in
the skeletal muscles and plays a central role in the growth and regeneration of skeletal
muscles, the main pathogenesis of sarcopenia is contributed to the age-related functional
disability in satellite cells[129]; Parkinson’s disease (PD) is caused by the deposition of
Lewy bodies in the central nervous system, which further influences the motor system.
PD patients are suffering from movement-related problems, such as shaking, rigidity, and
difficulty with walking. Moreover, dementia commonly arises in the advanced stages of
disease[130]; Alzheimer’s disease is the most common cause of dementia, which triggers
the problems of communication, thinking, and memory. Numerous studies demonstrated
that the etiology of AD is due to the deposition of senile plaques (tau proteins and
amyloid beta proteins) in the neurons, which disrupt the neuron cells’ transduction
signaling induce neuron cell death[131]. Although the pathogenesis is different in these
neurodegenerative diseases, based on the previous research, there are some sub-cellular
level similarities shared among these diseases: the majority of neurodegenerative diseases
are engendered by genetic mutations and protein misfolding problems[132]. Discovering
of these molecular similarities of neurodegenerative diseases not only provided us more
opportunities to better understand how these diseases are generated but also helped us to
further investigate the efficient therapeutic treatments[133].
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Given that AD is a major type of age-related disorder and the most common cause of
dementia worldwide, our study focused on studying the molecular mechanism of AD.
1.3.2 Alzheimer’s Disease
1.3.2.1 The etiology of AD

AD is a major type of neurodegenerative disease and the number one cause of
dementia in the aging population. Brain atrophy and neuronal lesions are two obvious
phenotypes of Alzheimer’s disease, which cause problems with thinking, memory, and
behavior. The worldwide statistic data demonstrated that the number of AD patients will
approach 63 million by 2030 and 114 million by 2050[134]. Therefore, there is an urgent
need for scientists to develop efficient therapeutic treatment of AD.

To date, although a wealth of data surrounding AD has been published, the molecular
mechanism underlying this disease is still unclear. There are several accepted hypothesis
trying to explain the cause of AD. First, amyloid hypothesis is the most accepted theory
in aging research, which claimed that the deposits of extracellular amyloid beta (Aβ) are
the principal cause of neuron lesions. Amyloid precursor protein (APP) is considered to
be a major source of Aβ. In normal conditions, APP is split by α-secretase and formed
soluble αAPPs rather than toxic Aβ. However, β-secretase and γ-secretase could split
APP into three fragments and, in turn, certain peptide fragments could aggregate into
insoluble plaques in brain and therefore cause AD (Figure 1.3) [135]. One may note that
Aβ is considered as a hallmark of AD as well as an important target of anti-AD drugs.
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The second hypothesis is called tau theory. The tau proteins, a group of important
structural proteins in neuron cells, function to stabilize microtubules to maintain cell’s
cytoskeleton. It has been proposed that AD is initiated by tau protein abnormalities.
Based on the previous research, tau proteins are highly overexpressed in AD patients.
Specifically, the majority of these proteins are hyper-phosphorylated, which are prone to
pairing with others to form neurofibrillary tangles (PHF) inside nerve cells and thus result
in destroying and collapsing the neuron cells[136].

The third hypothesis, genetic heritability of AD, claimed that AD is an inherited
disease and well explained the etiology of early onset familial AD. The best known
genetic risk factor is the inheritance of the ε4 allele of the apolipoprotein E (APOE), and
people carrying the APOEε4 allele have higher risk to get AD. In addition to APOE, the
genetic mutations in TREM2, presenillins 1 and 2, and APP have been associated with
higher risk of developing AD[137]. Taken together, although the molecular mechanism
of AD is intricate and complex, scientists will develop efficient anti-AD treatment in the
near future.
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Figure 1.3 The formation of amyloid plaques and neurofibrillary tangles are
thought to contribute to the degradation of the neurons. (Modified from
BrightFocus Foundation, 2000)
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1.3.2.2 The treatment of AD

Although AD is an incurable disease, there are several medications to temporarily
mitigate the worsening of symptoms and slow the development of AD. From 1996 to
2004, the U.S Food and Drug Administration (FDA) has approved five medications to
treat AD, including donepezil, galantamine, memantine, rivastigmine, and dopepezil[138].
Although these drugs could improve cognitive ability, it is still unknown whether these
medications could extend the lifespan of AD patients because these drugs are short-term
effect cholinesterase inhibitors[139].
In addition to these five FDA approved medications, Aβ inhibitors are also
considered as anti-AD treatments, such as Aβ vaccine, anti-inflammation drugs, and anticholesteric drugs. Clinical studies showed that these treatments are beneficial to prevent
AD and treat early stages of AD patients[140, 141].

To date, a growing body of evidence suggestes that dietary intervention is a good
choice to slow down the age-related disorders. Numerous studies showed that anti-aging
nutraceuticals could slow down the development of AD[142]. Moreover, reduction of IIS
pathway could alleviate Aβ toxicity in C. elegans and mammals (Figure 1.4)[143, 144].
For instance, coca could mitigate the Aβ toxicity by reducing its aggregation in AD
model, which is dependent on IIS pathway and DAF-16[97, 145]; Dostal and his
colleagues reported that coffee significantly reduced Aβ toxicity, and this anti-AD effect
required SKN-1[146]; Resveratrol, a SIR-2.1 activator, could protect neuron cells from
apoptosis and thereby delay the development of AD and Parkinson’s disease[147].
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Collectively, nutraceutical supplementation not only extends lifespan and increases stress
resistance, but also has beneficial effects to slow down the development of age-related
disorders.

Figure 1.4 Reduction of IIS pathway prevents neurodegeneration in worms and
human. (Moll et al., Swiss Med Wkly. 2014;144:w13917)
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1.3.3 Cellular Proteostasis

A growing body of evidence indicated that healthy aging is always associated
with well-maintained proteostasis[148]. The imbalance of protein homeostasis could
accelerate aging and induce neurodegenerative diseases. Proteostasis includes protein
synthesis, folding, aggregation and degradation, which is the process to control the
quality of cellular proteins[149]. Proteins are synthesized from ribosomes and folded to
form the functional conformation. The endogenous and exogenous stresses could damage
the proteins, forming the unfolded proteins. The unfolded and misfolded proteins could
be refolded by heat shock proteins or be targeted by ubiquitin proteasome and lysosomal
pathways to destruction and degradation[150]. This mechanical system keeps the
function proteostasis in the health cells to keep the integrity of proteome and promote the
cellular renewal[151]. However, in the aging cells or chronic persisting stresses
conditions, this system is overwhelmed, which could form the aggregations and increase
the proteotoxicity, which could increase the risk of neurodegenerative diseases.
Functional proteostasis could improve healthy aging and reduce the risk of age related
disorders development (Figure 1.5).
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Figure 1.5 Proteostasis is the Process to Control the Quality of Cellular
Proteins. (López-Otín et al., 2013)
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CHAPTER TWO : MATERIAL AND METHODS
2.1 Experimental Procedures- longevity and stress response research
2.1.1 Strains and Growth Conditions

All wildtype strain and mutant strains were maintained at 20°C on NGM
(nematode growth medium) seeded with Escherichia coli OP50 feeding strain. A 100µl
of OP50 was dropped on the center of 60 mm NGM plates, which were allowed to dry
overnight before the assays were carried out. Strains used in this research were: N2
(Bristol, wild type), daf-16 (mgDf50), sir-2.1 (ok434), daf-12 (e1370), age-1 (hx-546), ftt2(n4426), and hcf-1(ok559). All the strains were obtained from the Caenorhabditis
Genetic Center (CGC), University of Minnesota, USA.
2.1.2 Preparation of RJ and eRJ

The powder of RJ and eRJ were provided by Yamada Apiculture Center, Inc.,
Okayama, Japan. To prepare RJ and eRJ supplemented food, appropriate amount of RJ or
eRJ in powder form were dissolved in sterile distilled water and suspended into the liquid
NGM one day before the assay.
2.1.3 Lifespan Assay

All lifespan assays were carried out at 25°C. Synchronized populations were
obtained by allowing 10-20 hermaphrodites lay eggs for 4 hours at 25°C and then
removing the parents. The eggs were allowed to hatch and develop. Approximately thirty
L4/young adult worms per plate (NGM plate contains 50 µg/mL FUDR to prevent the
growth of progeny) were used for each assay. All the assays were carried out in triplicates
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and a minimum of three independent trials were performed for all conditions. The dead
worms were counted starting the day after transfer and exploding, protruding, bagging, or
contaminated worms were censored if applicable. We defined the day when we
transferred the L4/young adult worms as day 0 of adult age. All statistical analyses were
carried out using SPSS software (IBM SPSS Statistics). Kaplan-Meier lifespan analysis
was carried out and p values were calculated using the log-rank test. p <0.05 was
accepted as statistically significant.
2.1.4 Growth Curve of E.coli OP50

The overnight culture of E.coli OP50 was 1:100 diluted in LB (200mg/mL
Streptomycin), shaking at 37°C. RJ (2mg/mL) and eRJ (1mg/mL) were added in the LB
medium respectively, bacteria treated without RJ/eRJ served as controls. All the bacteria
were cultured at 37°C shaker and measured the OD600 reading every hour to compare
the difference between each treatment.
2.1.5 Stress Assays

For three stress assays, wildtype N2 worms were pre-treated with 2mg/mL RJ or
1mg/mL eRJ respectively for two generations at 25°C on OP50 seeded NGM plates.
Worms on regular NGM OP50 seeded plates without RJ and eRJ served as controls. Each
assay was carried out in three independent trials, and the data were pooled and analyzed
using Student’s t test. p<0.05 was accepted as statistically significant.
For the oxidative stress assay, 5 mM paraquat (sigma-Aldrich, Corp., St Louis,
MO) was used to induce the oxidative stress environment. The RJ/eRJ-pretreated

29

L4/young adult worms and their controls were transferred onto NGM plates containing
5mM paraquat, and survival was assessed by daily counting until all worms died.
To assay for the protective effect on UV irradiation, RJ/eRJ pretreated L4/young
adult worms and controls were transferred to RJ/eRJ (2mg/mL RJ and 1 mg/mL eRJ)
plates and regular NGM plates respectively, and were irradiated at 0.05 J/cm2 for 20
seconds. The survival of the worms was monitored at 25°C.
For the heat shock assay, RJ/eRJ pretreated L4/young adult stage worms and
controls were transferred to RJ/eRJ supplemented (2mg/mL RJ and 1 mg/mL eRJ) plates
and regular NGM plates respectively. The plates were incubated at 35°C for 3 hours and
then transferred back to 25°C. The survival of worms was monitored daily.
2.1.6 Brood Size and Body Bend Assays

The brood size assay was carried out by counting the offspring of a single worm
on an NGM plate supplemented with or without RJ/eRJ (2mg/mL RJ and 1 mg/mL eRJ).
Each L4/young worm was allowed to lay eggs at 25°C for 24 hours and was then
transferred to a fresh plate until it ceased to lay eggs. The offspring were counted after
they reached L3 or L4 phase. This assay was carried out in three independent trials. The
data were pooled and analyzed using Student’s t test. p < .05 was accepted as statistically
significant.
For the motility assay, worms were pre-treated with or without RJ/eRJ (2 and
1mg/mL, respectively) for two generations on NGM plates at 25°C. Three or four RJ/eRJ
pretreated and non-treated L4/young adult nematodes were placed onto individual NGM
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plates without OP50. The number of body bends performed in 3 minutes was counted,
and then the number of body bends per minute was calculated. This assay was carried out
in three independent trials. The data were pooled and analyzed using Student’s t
test. p < .05 was accepted as statistically significant.
2.1.7 DAF-16 Translocation Assay

daf-16 (mgDf47) I; xrIs87 worms carrying a DAF-16-GFP fusion construct (Lee
et ql., 2001) were treated respectively with eRJ (1mg/mL) or RJ (2mg/mL) for two days
and were then observed under a fluorescence microscope (Nikon AZ100) to monitor the
nuclear translocation of DAF-16-GFP.
2.1.8 Gene Expression Analysis by Quantitative RT-PCR

The nematodes were grown on NGM plates supplemented with or without RJ/eRJ
at 25°C, until they reached the young adult stage, then collected in M9 buffer. RNA was
prepared using RNAzol® RT reagent (Molecular Research Center, Inc.) and stored at –
80°C. Complementary DNA was prepared by using Invitrogen Superscript first strand
synthesis system for RT–PCR (Invitrogen). Quantitative PCR (qPCR) was performed
using SsoFast EvaGreen Supermix and the CFX96 real-time PCR detection system
according to the manufacturer suggested protocol (Bio-Rad). The qPCR conditions were:
95°C for 3 minutes, followed by 40 cycles of 10 seconds at 95°C and 30 seconds at
60°C. act-1 was used as an internal control to normalize the expression levels of target
transcripts. Each qPCR experiment was repeated three times using independent RJ/eRJ
treatments and RNA preparations. The data were pooled and analyzed using Student’s
t test, and p < .05 was accepted as statistically significant.
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The qPCR primers for sod-3 are: 5′-CCAACCAGCGCTG-AAATT CAATGG-3′
(forward primer (F)) and 5′-GGAACCGAA GTCGCGCTTAATAGT-3′ (reverse primer
(R)). Primers for daf-16 are 5′-CCAGACGGAAGGCTTAAACT-3′ (F) and 5′-ATTCGC
ATGAAACGAGAATG-3′ (R). Primers for sir-2.1 are 5′-AGAACGCGCATTTCGCC
ATATTAAG-3′ (F) and 5′-ATACTGACACTCCAGCGCCAG-3′ (R). Primers for hcf1 are 5′-GCGTTTACTTGGCCGTTAAGAATC-3′ (F) and 5′-GCCGTTCCCAGGTTTG
ATTG-3′ (R). Primers for C32H11.4 are 5′-TTACTTCCCATCGCCAAAGT-3′ (F) and
5′-CAATTCCGGCGATGTATGAT-3′ (R). Primers for F21F3.3 are 5′-CCGATTCGTT
CCTTTTGAAG-3′ (F) and 5′-ACAACCGAATGTTCCAATCC-3′ (R). Primers for mtl1 are 5′-ATGGCTTGCAAGTGTGACTG-3′ (F) and 5′-CACATTTGTCTCCGCACTT
G-3′ (R). Primers for act-1 are 5′-CCAGGAATTGCTGATCGTATGCAGAA-3′ (F) and
5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R).
2.2 Experimental Procedures- C. elegans Alzheimer’s Disease Model Research
2.2.1 Strains and Growth Conditions

All strains were maintained at 16 °C on nematode growth medium (NGM) seeded
with Escherichia coli OP50 feeding strain. Strains used in this study were as follows: N2
Bristol (wild type), CL2006 (AD worm), and daf-16 (mgDf50). All the strains were
obtained from the Caenorhabditis Genetics Center (CGC), University of Minnesota.
2.2.2 Preparation of RJ and eRJ

The powder of RJ and eRJ were provided by Yamada Apiculture Center, Inc.,
Okayama, Japan. To prepare RJ and eRJ supplemented food, appropriate amount of RJ or
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eRJ in powder form were dissolved in sterile distilled water and suspended into the liquid
NGM (2mg/mL RJ and 1mg/mL eRJ) one day before the assay.
2.2.3 RNA Interference

RNA interference (RNAi) clones were grown overnight at 37 °C on Luria Broth
plate in the presence of tetracycline (12.5 µg/ml) and carbenicillin (25 µg/ml). Bacterial
colonies were inoculated and grown for 8–12 hours, then induced with 2mM isopropyl βD-1-thiogalactopyranoside (IPTG) for 4 hours at 37 °C. Ten-fold concentrated RNAi
bacteria were seeded onto RNAi plates containing 25 µg/ml carbenicillin. The RNAi
constructs targeting daf-2, age-1, daf-16, hsf-1, skn-1, jnk-1, sir-2.1, hcf-1 and ftt-2 were
obtained from the C elegans ORFeome RNAi library v1.1.
RNAi efficiencies were checked at the same time with RNAi paralysis assay.
CL2006 worms were synchronized by allowing 10–15 hermaphrodites lay eggs 6 hours
on RNAi bacteria seeded NGM plates at 16 °C. The eggs were allowed to hatch and
develop. The L4 /young adult worms were transferred to RJ/eRJ (2mg/mL RJ and
1mg/mL eRJ, respectively) NGM plates (containing 50 µg/mL FUDR to prevent the
growth of progeny) to maintain for 6 days. CL2006 worms on regular NGM (FUDR)
plates without RJ/eRJ served as controls. Worms at the 6-day old stage were collected
with M9 buffer into a 50~100 µl pellet. RNA extraction and qPCR method are described
in 2.1.8.
The qRT-PCR primers for daf-16 are as follows: 5′-CCAGACGGAAGGCTTA
AACT-3′ (F) and 5′-ATTCGCATGAAACGAGAATG-3′ (R). Primers for hsf-1 are as
follows: 5’-TTGACGACGACAAGCTTCCAGT-3’(F) and 5’-AAAGCTTGCACCAG
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AATCATCCC-3’(R). Primers for skn-1 are as follows: 5’-GTAGCCGACGACGAAG
AAGA-3’(F) and 5’-GAATTGAGGTGTTGGACGAT-3’(R). Primers for sir-2.1 are as
follows: 5′-AGAACGCGCATTTCGCCATATTAAG-3′ (F) and 5′-ATACTGACACTC
CAGCGCCAG-3′ (R). Primers for hcf-1 are as follows: 5′-GCGTTTACTTGGCCGTTA
AGAATC-3′ (F) and 5′-GCCGTTCCCAGGTTTGATTG-3′ (R). Primers for ftt-2 are as
follows: 5’-TCGACAAGTTCCTCATTCCA-3’(F) and 5’-TAGCTTTGCTGCGACTTC
TC-3’(R). Primers for daf-2 are as follows: 5’-CGGTGCGAAGAGAGGATATT-3’(F)
and 5’-TACAGAGGTCGCCGTTACTG-3’(R). Primers for age-1 are as follows: 5’AGTGGATTCGGAAACAATGC-3’(F) and 5’-GGAATCGATCGACACTTTCA-3’ (R).
Primers for jnk-1 are as follows: 5’-ACAGTGGAACAGGAGGAGG-3’(F) and 5’ATACGGAAGTGGAGGTGGAG-3’ (R). Primers for act-1 are 5′-CCAGGAATTGC
TGATCGTATGCAGAA-3′ (F) and 5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R)
2.2.4 Lifespan Assays

All lifespan assays were carried out at 20 °C. Synchronous populations were
obtained by allowing 10–15 hermaphrodites lay eggs overnight at 16 °C, and the parents
were removed the next day. The eggs were allowed to hatch, and 30 L4/young adult
worms per plate (NGM plate containing 50µg/ml 5-fluorour-aci1-2′-deoxyribose to
prevent the growth of progeny) were used for each assay. The dead worms were counted
starting the next day, and exploding, protruding, bagging, or contaminated worms were
censored if applicable. We defined the day when we transferred the L4/young adult
worms as Day 0 of adult age. All the assays were carried out in triplicates, and a
minimum of three independent trials were performed for all conditions. All statistical
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analyses were carried out using SPSS software (IBM SPSS Statistics). Kaplan–Meier life
span analysis was carried out, and p values were calculated using the log-rank
test. p <0.05 was accepted as statistically significant.
2.2.5 Worm Paralysis Assays

The assays using strain CL2006 were carried out as described by Cohen and
colleagues. Synchronous populations of CL2006 worms were prepared on NGM plates
by allowing 10–15 hermaphrodites lay eggs overnight at 16 °C, and the parents were
removed the next day. The eggs were allowed to hatch, and 20 L4/young adult worms per
plate were used for each assay. All paralysis plots were done in triplicates, and a
minimum of three independent trials were performed per condition. Nematodes were
scored as paralyzed if they exhibited “halos” of cleared bacteria around their heads
(indicative of insufficient body movement to access food) or failed to undergo full body
wave propagation upon the nose prodding. Worms were checked every day until all
worms were paralyzed. The data were pooled, and the percentage of paralyzed worms
was calculated and analyzed using Student’s t-test. p < 0.05 was accepted as statistically
significant.
2.2.6 Western Blotting of Aβ Species

Rabbit polyclonal Aβ1–42 primary antibodies were from abcam (ab39377). For
Western blot analysis, CL2006 worms were synchronized by allowing 10–15
hermaphrodites to lay eggs overnight on OP50 seeded NGM plates at 16 °C. The parents
were removed, and eggs were allowed to hatch and develop to the L4 stage. Subsequently,
worms were transferred to RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively)
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containing NGM plates and continued to grow at 20 °C. CL2006 worms on regular NGM
plates without RJ/eRJ served as control. After 10 days of growth, worms were transferred
to micro-centrifuge tubes and washed with S-basal followed by protein immobilization
on polyvinylidenefluoride (Bio-Rad) membrane. Polyvinylidenefluoride membrane was
incubated with primary antibodies (1:1,000) diluted in 5% nonfat dry milk and then with
secondary, HRP-conjugated goat anti-rabbit antibodies (Genscript, A00098; diluted
1:10,000). ACTIN was used as loading control, and the anti-ACTIN antibodies
(MAB1501) were from EMD Millipore. Detection was undertaken with standard ECL
protocol. Mean intensity of Aβ signals was analyzed using Image-J software (National
Institute of Health).
2.2.7 Soluble Protein Extraction

The soluble protein extraction was performed as described previously with
alterations. Synchronous populations of eggs were prepared by 20% alkaline hypochlorite
treatment of gravid adults grown at 16 °C. Eggs were allowed to hatch and develop by
transferring to OP50-seeded NGM plates containing RJ/eRJ (2mg/mL RJ and 1mg/mL
eRJ, respectively) at 20 °C. Eggs hatched and developed on OP50-seeded NGM plates
without RJ/eRJ served as controls. Both worms treated with or without RJ/eRJ
supplementation were collected 10 days after L4 stage. Three separate replicates of each
sample (about 200mg [wet weight] of worms) were collected. Total protein extracts were
produced in phosphate-buffered saline by sonication on ice, and then the total protein
concentration was determined by conducting a bicinchoninic acid assay. Next, the
normalized protein samples were centrifuged for 10 minutes at 14,000g to remove the
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insoluble fraction. The same volume of supernatants (soluble fraction) was loaded and
analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Mean intensities
of protein bands were analyzed using Image-J software (National Institute of Health).
2.2.8 Gene Expression Analysis by Quantitative Real-time PCR

CL2006 worms were synchronized by allowing 10–15 hermaphrodites lay eggs 6
hours on OP 50 seeded NGM plates at 16 °C. The eggs are allowed to hatch and develop.
The L4 /young adult worms were transferred to RJ/eRJ (2 and 1mg/mL respectively)
NGM plates (containing 50 µg/mL FUDR to prevent the growth of progeny) to maintain
for 6 days. CL2006 worms on regular NGM (FUDR) plates without RJ/eRJ served as
controls. Worms at the 6-day old stage were collected with M9 buffer into a 50~100 µl
pellet. RNA extraction and RT-PCR method are described in 2.1.8.
The qRT-PCR primers for daf-16 are as follows: 5′-CCAGACGGAAGGCT
TAAACT-3′ (F) and 5′-ATTCGCATGAAACGAGAATG-3′ (R). Primers for hsp12.6 are as follows: 5′-ATGATGAGCGTTCCAGTGATGGCTGACG-3′ (F) and 5′TTAATGCATTTTTCTTGCTTCAATGTGAAGAATTCC-3′ (R). Primers for hsp16.2 are as follows: 5′-TTGCCATCAATCT CAACGTC-3′ (F) and 5′-CTTTCTTT
GGCGCTTCAATC-3′ (R). Primers for hsp-70 are as follows: 5′-CGTTTCGAAGA
ACTGT GTGCTGATCTATTCCGG-3′ (F) and 5′-TTAATCAACTTCCTCA ACA
GTAGGTCCTTGTGG-3′ (R). Primers for act-1are as follows: 5′- CCAGGAATTG
CTGATCGTATGCAGAA-3′ (F) and 5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R).
Primers for sod-3 are as follows: 5′-CCAACCAGCGCTG-AAATT CAATGG-3′ (F) and
5′-GGAACCGAA GTCGCGCTTAATAGT-3′ (R). Primers for mtl-1 are as follows: 5′-
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ATGGCTTGCAAGTGTGACTG-3′ (F) and 5′-CACATTTGTCTCCGCACTTG-3′ (R).
Primers for sip-1 are as follows: 5’- GGTCAATCTTGAGGGACACG-3’ (F) and 5’GAGTGAACGATCTCTTGCTG-3’ (R). Primers for aip-1 are as follows: 5’GAGCGGGATCACAGTTGTGAG-3’ (F) and 5’- GATGTGATTGAATCCGTCCAG-3’
(R). Primers for F10D7.5 are as follows: 5’- GCACTAGAGGACCATTACAGTT-3’ (F)
and 5’- CGTTCTCGTCAATCTCGATAGG-3’ (R). Primers for ZK218.8 are as follows:
5’- TGCTACTGGCTGTGTGTTAG-3’ (F) and 5’- CAATAGTTCCGGCATTCACATA
AT-3’ (R). Primers for T05G5.10 are as follows: 5’- GGAGACTTGGGAAACACTATC
C-3’ (F) and 5’- TGTATCCGAGAATAGCCTCCT-3’ (R). Primers for Y71H2AR.2 are
as follows: 5’- GAGTTGTGGCAGAGGGTAATG-3’ (F) and 5’- GGATGGGTTGTAG
ATTCCGATTT-3’ (R).
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CHAPTER THREE : THE MOLECULAR MECHANISM OF ROYAL JELLY
MEDIATED LIFESPAN EXTENSION
3.1. Introduction

Aging is an inevitable process associated with physiological decline and higher
risk to get disease. Nowadays because of the development of technology and medical
treatment, the population structure changed and population aging already became a
challenging issue to our society. Age-related diseases affect aging population and their
families; moreover, the increasing medical cost brings concerning economic burden to
the society and government. In order to solve this problem, more and more scientists are
dedicated to doing research in the anti-aging field, not only study the molecular
mechanism of aging, but also look for effective methods to delay the onset of age-related
disorders. Although the anti-aging research field is very new, it is extremely urgent for
scientists to find out efficient solutions to slow down the age-related diseases
development, therefore, improving the aging populations’ quality of life.
As same as other biological processes, aging is also controlled by genes[31].
Insulin like signaling (IIS) pathway is considered as a master regulator to modulate
longevity and metabolism. DAF-16 is a downstream component of IIS pathway, which
functions as an essential transcriptional factor to regulate cell proliferation, metabolism,
and longevity[38]. Similar to other transcriptional factors, DAF-16 is tightly controlled
by other co-factors. SIR-2.1, HCF-1 and 14-3-3 are reported as major DAF-16 co-factors
and physically interact with DAF-16 to regulate its activity[62].
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It is well known that dietary intervention and genetic alteration could manipulate
genes and pathways to regulate longevity in the anti-aging research field[152].
Comparing to other methods, dietary intervention is the most efficient and safe manner to
delay the development of age related disorders[88]. Royal Jelly is a popular functional
food in Asian market, which has a series of beneficial effects of health. As a bee product,
Royal Jelly is secreted from the pharyngeal glands of nurse worker bees (Apis mellifera)
to feed larvae. Adult queens are fed only with Royal Jelly for the whole life and it enables
her to outlive worker bees nearly thirty fold. Most people believe that Royal Jelly might
have the pro-longevity factors, and the Japanese scientists confirmed this hypothesis[105].
They reported that Royal Jelly has the anti-aging beneficial effects, but the mechanism is
still unclear. In my research, I will focus on investigating the molecular mechanism of
Royal Jelly’s anti-aging functions.
Our Royal Jelly powders were provided by Yamada Japanese Company, and there
were two types of Royal Jelly powders used in our research; one was enzyme treated
Royal Jelly (eRJ), and the other was regular Royal Jelly (RJ). Caenorhabditis elegans (C.
elegans) was used as a model animal to investigate RJ/eRJ’s anti-aging function. Our
data showed that RJ/eRJ supplementation extended C. elegans lifespan in a dose
dependent manner. IIS/DAF-16 and DAF-16’s co-factors were required in this RJ/eRJ
mediated lifespan extension. Our proposed model was: under the supplementation of
RJ/eRJ, SIR-2.1, HCF-1 and 14-3-3 could interplay with DAF-16 to fine-tune its
transactivity to extend C. elegans lifespan.
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3.2. Experiment Results
3.2.1 Supplementation of RJ/eRJ extends C. elegans lifespan in a dose-dependent
manner

In order to determine whether RJ/eRJ has the pro-longevity beneficial effects, we
treated the wild type C. elegans (N2 worms) with different concentrations of Royal Jelly,
ranging from 0mg/mL to 5mg/mL, and carried out the lifespan assays to observe worms’
survival at 25°C. Our results showed that N2 worms treated without RJ/eRJ (control
group) showed a regular lifespan. The mean lifespan was 12.79 days. Afterwards we
compared the mean lifespan of RJ/eRJ supplemented worms to control worms to
investigate whether RJ/eRJ could extend the lifespan of C. elegans.
In RJ treatment, the mean lifespan of 0.4mg/mL RJ treatment was 0.23 day longer
than non-supplemented controls, but this lifespan extension was not significant. For the
higher concentration RJ treatment, 1mg/mL to 3mg/mL RJ significantly increased C.
elegans mean lifespan from 12.79 days to 13.52days, 15.52 days, and 14.39 days,
respectively. However, the highest concentration 5mg/mL RJ hardly influenced C.
elegans mean lifespan (Figure 3.1 A and Table 1). Based on this result, we found out the
best concentration of RJ for lifespan extension was 2mg/mL, which increased 21.34% of
lifespan comparing to control group.
In eRJ treatment, low concentration of eRJ (0.4mg/mL) showed a similar lifespan
as the control group, which indicated that this low concentration of eRJ cannot extend N2
worms’ lifespan. For the higher concentration of eRJ treatment, 1mg/mL to 3mg/mL eRJ
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could extend worms’ lifespan significantly, from 12.79 days to 14.44 days, 14.09 days,
and 13.95 days, respectively. However, the highest concentration 5mg/mL eRJ barely
affected C. elegans mean lifespan (Figure 3.1 B and Table 1). Based on this result, we
found out that the best concentration of eRJ treatment was 1mg/mL, which increased
11.33% of lifespan comparing to control group.
Taken together, the lifespan results showed that both RJ and eRJ could extend
C.elegans lifespan in a dose-dependent manner. A 2mg/mL RJ and 1mg/mL eRJ were
selected as the optimum concentrations to prolong C. elegans lifespan.
Several papers published that Royal Jelly also has anti-pathogen functions. In our
experiment, worms were fed with E.coli OP50 as their regular food, and we questioned
whether Royal Jelly’s anti-aging effect is dependent on inhibiting the growth of E.coli or
attenuating the expression of its virulent factors expression. In order to answer this
question, we cultured E.coli OP50 in LB medium with RJ/eRJ respectively and observed
their growth curve. We observed that RJ/eRJ did not inhibit the E.coli OP50 growth at
any bacterial growth phases, on the contrary, RJ/eRJ increased E.coli OP50 growth at the
lag phase and log phase, which indicated that RJ/eRJ mediated lifespan extension did not
act through its anti-pathogen effects (Figure 3.2).
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Figure 3.1 RJ/eRJ extends C. elegans lifespan in a dose-dependent manner.
Wild-type N2 worms were treated with RJ (A) or eRJ (B) at 0-5mg/mL. Each lifespan
experiment was repeated at least three independent times with similar results. Quantative
data and statistical analyses for the representative experiments are included in Table 1.
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Table 1 The Lifespan of Wildtype Worms Stain at 25°C
Stain
N2
N2+ 0.4 mg/mL RJ*
N2+ 1mg/mL RJ*
N2+ 2mg/mL RJ*
N2 + 3mg/mL RJ*
N2+ 5mg/mL RJ*
N2+ 0.4 mg/mL eRJ**
N2+ 1mg/mL eRJ**
N2+ 2mg/mL eRJ**
N2+ 3mg/mL eRJ**
N2+ 5mg/mL eRJ**

Mean±SE
12.97±0.32
13.02±0.30
13.52±0.33
15.52±0.23
14.39±0.22
12.64±0.43
12.97±0.30
14.44±0.24
14.07±0.20
13.95±0.22
12.68±0.40

Median
13.00
13.00
14.00
16.00
15.00
13.00
13.00
15.00
14.00
14.00
13.00

No.of Worms
52
62
52
52
62
59
49
45
74
62
50

p value
0.320
0.017
<0.001
<0.001
0.543
0.867
<0.001
0.001
0.003
0.699

Note: Lifespan and standard error are shown in days. The lifespan experiments were
repeated at least three times with similar results. And the data for representative
experiments were shown. The lifespan data were analyzed using the log-rank test and p
values for each individual experiment are shown.
*Results presented in Figure 3.1 A

**Results presented in Figure 3.1 B
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Figure 3.2 RJ/eRJ cannot affect E.coli OP50 growth. E.coli OP50 were cultured
with RJ/eRJ and OD600 were measured every hour to observe the growth curve.
Experiment was repeated at least three independent times with similar results.
Student t test showed p value was >0.05, quantitative data and statistical analyses
were analyzed in excel.
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3.2.2 RJ/eRJ barely Influences Reproductive Capacity and Motility of C. elegans.

Given that RJ/eRJ could extend C. elegans lifespan, 2mg/mL RJ and 1mg/mL eRJ
were selected as the optimum concentration to promote longevity. Next, we wondered
whether RJ/eRJ affected the physiological indexes of C. elegans. In order to address this
question, brood size (reproductive parameter) and motility were tested to check worms’
reproductive capacity and general fitness ability under RJ/eRJ supplementation.
In the brood size test, N2 worms were treated with or without RJ/eRJ for two
generations, afterwards the total offspring numbers of wild type worms were counted
under each treatment. The results showed that the average of total offspring number was
206 per worm in the control group, while the RJ/eRJ treated worms had the similar
number when compared with the controls. This brood size result indicated that RJ/eRJ
cannot affect worms’ total offspring quantity (Table 2).
In the motility test, worms were treated with or without RJ/eRJ supplement for
two generations, afterwards ten synchronized young adult worms from each treatment
were transferred to non-seeded NGM plates and the body bends per minute were counted
to check their moving ability. Our data showed that the average body bends per minute of
one worm was 13.9 in the control group, while the RJ/eRJ treated worms had similar
body bends times when compared with the controls. This result demonstrated that RJ/eRJ
barely affected worms’ moving ability (Table 2). Taken together, our results suggested
that RJ/eRJ mediated lifespan extension is not associated with any significant changes in
reproductive capacity and motility of C. elegans.
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Table 2. RJ/eRJ Supplementation Does Not Influence Motility and
Reproductive Capacity of Caenorhabditis elegans at 25°C

Brood
Size
Motility

control±SE

RJ-Treated
±SE

eRJTreated±SE

p value

Total No. of
Worms

206±23.6
13.9±1.0

194±18.9
14.1±1.5

203±24.7
13.8±1.2

0.37*, 0.84†
0.79*, 0.81†

6*, 6†, 6ⱡ
10*, 10†, 10ⱡ

Notes: These data represent the average of three independent trials for each test.
*RJ-treated worms.
†eRJ-treated worms.
ⱡControl worms.
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3.2.3 Supplementation of RJ/eRJ Modulateds C. elegans Lifespan through the IIS
Cascade and DAF-16

Our lifespan assays revealed that RJ/eRJ could extend C. elegans lifespan in a
dose dependent manner. Next we want to know the molecular mechanism underlying this
beneficial effect. It is well known that Insulin like signaling pathway (IIS pathway) is one
of the most powerful pathways to regulate cell proliferation, metabolism, and longevity.
We questioned whether RJ/eRJ mediated lifespan extension is dependent on the
regulation of IIS pathway. First of all, we examined whether DAF-16, an important
transcriptional factor of IIS pathway, was involved in the RJ/eRJ mediated anti-aging
function. We treated null daf-16 (mgDf50) mutant worms with RJ (2mg/mL) and eRJ
(1mg/mL) respectively and counted lifespan under 25°C. Our data showed that the mean
lifespan of non-supplemented daf-16 deletion mutants was 6.85 days, and the mean
lifespan of RJ and eRJ treatment was 6.91 days and 6.74 days respectively (Figure 3.3 A
and B, and Table 3). This finding suggested that DAF-16 was required in RJ/eRJ
mediated lifespan extension effect.
Next, we tested whether DAF-2 and AGE-1, two major components of the IIS
pathway, were required in RJ/eRJ mediated lifespan extension.. The mutant worms daf-2
(e1370) were treated with RJ (2mg/mL) and eRJ (1mg/mL) respectively and lifespan was
counted under 25°C. Our data showed that the mean lifespan of non-supplemented daf-2
(e1370) mutants was 26.68 days, and the mean lifespan of RJ and eRJ treatment was
26.99 days and 27.01 days respectively (Figure 3.3 C and Table 3). Similarly, the mean
lifespan of non-supplemented age-1 (hx546) mutants was 27.08 days, and the mean
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lifespan of RJ and eRJ treatment was 27.31 days and 27.00 days respectively (Figure 3.3
D and Table 3). This result indicated that RJ/eRJ acted, at least in part, through the IIS
pathway and DAF-16 to increase lifespan in C. elegans.
Considering that the IIS pathway regulates lifespan in C. elegans by limiting
DAF-16 nuclear trans-localization, we postulated that RJ/eRJ treatment might affect
DAF-16 nuclear localization and transcriptional activities. In order to check the DAF-16
nuclear localization, we examined subcellular localization of DAF-16 using transgenic
worms overexpressing DAF-16::GFP (daf-16(mgDf47;xrls87)), which showed GFP
signal in almost all somatic cells. Specifically, the DAF-16::GFP worms were
supplemented with RJ/eRJ on NGM plates from the early L1 stage until day 2 adults.
Afterwards the DAF-16::GFP signal in live worms (day 2 adults) was observed under a
fluorescent microscope (Nikon AZ100). Unfortunately, we did not observed a significant
increase of DAF-16-GFP in the nucleus after treatment of either RJ or eRJ (data not
shown).
In order to test how DAF-16 is modulated in RJ/eRJ mediated lifespan extension,
we chose several DAF-16 target genes to check whether DAF-16 activity is influenced in
the RJ/eRJ supplementation treatments. Wild type N2 worms were treated with or
without RJ/eRJ for two generations and then the target genes expressions were tested by
quantitative PCR methods. The result showed that the mRNA level of DAF-16 was not
changed when compared to non-supplemented controls, but its target genes expressions
were significantly affected. sod-3 is an important biomarker of DAF-16, which could
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reflect the DAF-16 activity obviously. Moreover, mtl-1, C32H11.4 and F21F3.3 are
DAF-16 target genes, which were selected in this experiment to check DAF-16’s
transactivity. Based on our quantitative PCR results, the elevated expression of sod-3,
mtl-1, F21F3.3 and reduced expression of C32H11.4 showed that DAF-16 activity was
up-regulated in the RJ/eRJ supplementary treatments (Figure 3.3 E).
Taken together, these findings suggested that RJ/eRJ treatment prolonged C.
elegans lifespan, which were dependent on promoting transcriptional activities of DAF16 rather than improving the accumulation of DAF-16 in nuclei.
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Figure 3.3 Both RJ and eRJ modulate Caenorhabditis elegans life span through
the IIS pathway and DAF-16. (A) daf-16(mgDf50) mutant worms were treated with
2mg/mL RJ. (B) daf-16 (mgDf50) mutant worms were treated with 1mg/mL eRJ. (C) daf2(e1370) mutant worms were treated with either 2mg/mL RJ or 1mg/mL eRJ. (D) age1(hx546) mutant worms were treated with either 2mg/mL RJ or 1mg/mL eRJ. Each lifespan experiment was repeated at least three independent times with similar results.
Quantitative data and statistical analyses for the representative experiments are included
in Table 1. (E) The transcript levels of daf-16, sod-3, mtl-1, C32H11.4, F21F3.3,sir-2.1,
and hcf-1 in N2 worms treated with and without 2mg/mL RJ or 1mg/mL eRJ were
quantified using qRT–PCR. The data from three independent experiments were pooled to
calculate the mean RNA level normalized to the internal control act-1. The standard
errors of the mean (SEM) were shown. The normalized mean RNA level of controls in
non-treated N2 worms were set to 1. *p < .05 compared with non-treated control.
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Table 3. The Lifespan Data of Worms Strains at 25°C
strain
N2*
N2+ 2mg/mL RJ*
daf-16(mgDf50)*
daf-16(mgDf50) + 2mg/mL RJ*
N2**
N2+ 1mg/mL eRJ**
daf-16(mgDf50)**
daf-16(mgDf50) + 1mg/mL eRJ**
N2†
N2+ 2mg/mL RJ†
N2+ 1mg/mL eRJ†
daf-2(e1370)†
daf-2(e1370) + 2mg/mL RJ†
daf-2(e1370) + 1mg/mL eRJ†
N2ⱡ
N2+ 2mg/mL RJⱡ
N2 + 1mg/mL eRJⱡ
age-1(hx546)ⱡ
age-1(hx546) + 2mg/mL RJⱡ
age-1(hx546) + 1mg/mL eRJⱡ

Mean±SE
13.48±0.22
15.57±0.28
7.21±0.23
6.74±0.26
12.65±0.34
14.40±0.37
6.85±0.23
6.91±0.19
12.64±0.30
14.29±0.35
13.86±0.31
26.68±0.52
26.99±0.55
27.01±0.48
12.14±0.24
13.53±0.28
13.32±0.33
27.08±0.56
27.31±0.50
27.00±0.42

Median
14.00
16.00
7.00
7.00
13.00
15.00
7.00
7.00
12.00
14.00
14.00
27.00
27.00
27.00
12.00
14.00
13.00
27.00
27.00
27.00

No. of Worms
64
58
84
65
57
45
72
78
80
80
92
79
67
80
81
63
60
79
89
78

p value
<0.001
0.216
<0.001
0.874
<0.001
0.003
0.726
0.910
<0.001
0.001
0.672
0.179

Notes: Life span and standard error are shown in days. The life-span experiments were
repeated at least three times with similar results, and the data for representative
experiments were shown. The life-span data were analyzed using the log-rank test
and p values for each individual experiment were shown.
*Results presented in Figure 3.3 A.

** Results presented in Figure 3.3 B.

†Results presented in Figure 3.3 C.

‡Results presented in Figure 3.3 D.
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3.2.4 RJ/eRJ Mediated Lifespan Extension is Modulated by SIR-2.1, and HCF-1, as
Well as FTT-2.

As an important transcriptional factor, DAF-16 is tightly controlled by several cofactors[73]. Next, we wondered whether DAF-16’s co-factors are involved in this RJ/eRJ
mediated lifespan extension. Previous studies reported that SIR-2.1, HCF-1, and 14-3-3
are important DAF-16 co-factors to modulate its transactivity. For instance, SIR-2.1
physically associates with DAF-16 via FTT-2, a 14-3-3 protein of C. elegans, to promote
the transactivation of DAF-16 under heat shock stress. Moreover, genetic and
biochemical studies demonstrated that, associated with 14-3-3 proteins, HCF-1 and SIR2.1/SIRT1 physically interacted and antagonized each other to fine-tune target gene
expressions DAF-16/FOXO and, in turn, to promot longevity and stress resistance[48, 62,
153].
First of all, we investigated whether SIR-2.1 was required in RJ/eRJ mediated
lifespan extension. Deletion mutant worms sir-2.1 (ok434) were treated with RJ/eRJ to
carry out lifespan assays. Our results showed that the mean lifespan of RJ/eRJ treatments
were 12.82 days and 12.74 days. As compared to the mean lifespan of non-supplemented
controls (12.82 days), we found out that RJ/eRJ cannot extend sir-2.1 (ok434) mutants
lifespan. This result suggested that SIR-2.1 was required in RJ/eRJ mediated lifespan
extension (Figure 3.4 A and B and Table 4).
Next, we tested whether RJ/eRJ modulated C. elegans lifespan dependent on
another two factors: 14-3-3 and HCF-1. Deletion mutant worms ftt-2 (n4426) and hcf-1
(ok559) were treated with 2mg/mL RJ or 1mg/mL eRJ, and lifespan assays were carried
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out under 25°C. For the ftt-2 (n4426) mutant worms, the mean lifespan of RJ/eRJ
treatments were 11.57 days and 11.51 days. As compared to mean lifespan of genotype
matched non-supplemented controls (11.67 days), we found out that RJ/eRJ cannot
extend ftt-2 (n4426) mutants lifespan (Figure 3.4 C and D and Table 4). Similarly, RJ/eRJ
supplementation failed to extend hcf-1 (ok559) mutant worms’ lifespan. Our data showed
that the mean lifespan of RJ/eRJ treatments were 15.79 days and 15.75 days, while the
mean lifespan of non-supplemented controls were nearly the same (15.94 days). These
results indicated that besides SIR-2.1, HCF-1, and 14-3-3 were also required in RJ/eRJ
mediated lifespan extension (Figure 3.4 E and F and Table 4).
Considering that either overexpression of SIR-2.1 or attenuation of HCF-1 can
extend C. elegans life span, we wondered whether RJ/eRJ supplementation extended
lifespan by altering the expression of SIR-2.1 and HCF-1. To address this concern, we
employed qPCR to measure the expression levels of sir-2.1 and hcf-1 with or without
RJ/eRJ supplementation. Our data showed that the mRNA levels of both sir-2.1 and hcf1were not significantly altered when compared with controls (Figure 3.3 E). Overall, our
findings suggested that RJ/eRJ modulated lifespan dependent, at least in part, on the
sophisticated interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 proteins.
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Figure 3.4 The RJ/eRJ requires SIR-2.1, HCF-1, and FTT-2 to
prolong Caenorhabditis elegans lifespan. (A) The sir-2.1 (ok434) mutant worms
were treated with 2mg/mL RJ. (B) The sir-2.1(ok434) mutant worms were treated with
1mg/mL eRJ. (C) The ftt-2 (n4426) mutant worms were treated with 2mg/mL RJ. (D)
The ftt-2(n4426) mutant worms were treated with 1mg/mL eRJ. (E) The hcf-1 (ok559)
mutant worms were treated with 2mg/mL RJ. (F) The hcf-1 (ok559) mutant worms were
treated with 1mg/mL eRJ. Each life-span experiment shown here was repeated at least
three independent times with similar results. Quantitative data and statistical analyses for
the representative experiments are included in Table 4.
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Table 4. The Lifespan Data of Worms Strains at 25°C
strain
N2*
N2 + 2mg/mL RJ*
N2 + 1mg/mL
eRJ*
sir-2.1 (ok434) *
sir-2.1 (ok434) + 2mg/mL RJ*
sir-2.1 (ok434) + 1mg/mL
eRJ*
N2†
N2 + 2mg/mL RJ†
N2 + 1mg/mL
eRJ†
ftt-2 (n4426)†
ftt-2 (n4426) + 2mg/mL RJ†
ftt-2 (n4426) + 1mg/mL eRJ†
N2ⱡ
N2 + 2mg/mL RJⱡ
N2 + 1mg/mL
eRJⱡ
hcf-1 (ok559)ⱡ
hcf-1 (ok559) + 2mg/mL RJⱡ
hcf-1 (ok559) + 1mg/mL eRJⱡ

Mean±SE
12.21±0.28
13.87±0.30

Median
12.00
14.00

No. of Worms
86
62

p value

13.28±0.28
12.82±0.19
12.82±0.19

13.00
13.00
13.00

81
68
84

0.015

12.74±0.24
12.56±0.20
14.57±0.28

13.00
13.00
15.00

62
121
58

0.630

14.40±0.37
11.67±0.29
11.57±0.52
11.51±0.30
12.21±0.28
13.87±0.30

15.00
12.00
13.00
12.00
12.00
14.00

55
124
51
77
86
62

<0.001

13.28±0.28
15.94±0.42
15.79±0.57
15.75±0.43

13.00
15.00
16.00
15.00

81
65
52
48

0.015

0.001

0.690

<0.001

0.795
0.318
0.001

0.977
0.629

Notes: Life span and standard error were shown in days. The lifespan experiments were
repeated at least three times with similar results, and the data for representative
experiments were shown. The lifespan data were analyzed using the log-rank test
and p values for each individual experiment were shown.
*Results presented in Figure 3.4 A and B.

†Results presented in Figure 3.3 C and D.

‡Results presented in Figure 3.4 E and F.
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3.3 Discussion

Aging causes the physiological decline and increases the risk of disease, which
brings a challenging question to society and encourages scientists to look for efficient
methods to slow down the development of age related disorders. Accumulation evidences
suggested that neutraceuticals, such as cranberry, cocoa, green tea, and herbal medicines,
provide a variety of health benefits to relay the aging process[91]. Several research labs
published that Royal Jelly, a bee product, has the lifespan extension function in C.
elegans model and alleviates type II diabetes disease in murine model. However, the
detailed molecular mechanism of Royal Jelly’s anti-aging effects remains elusive[103].
In this study, we utilized C. elegans as a model to investigate Royal Jelly’s antiaging function, we observed that regular Royal Jelly (RJ) and enzyme treatment Royal
Jelly (eRJ) could extend C. elengans lifespan in a dose dependent manner. Moreover,
RJ/eRJ did not affect C. elegans normal physiological traits, such as reproductive ability
and motility. Our genetic analysis indicated that Insulin like Signaling (IIS) pathway and
its important component DAF-16 were required in RJ/eRJ mediated lifespan extension.
Meanwhile, three DAF-16 co-factors, SIR-2.1, HCF-1, and 14-3-3, were also involved in
this beneficial effect. Our studies proposed a genetic model to elucidate the molecular
basis of RJ/eRJ’s pro-longevity function. Under the supplementation of RJ/eRJ, SIR-2.1,
HCF-1, and 14-3-3 are activated to fine-tune DAF-16 activity, and the sophisticated
interplay of these four proteins could regulate the expression of DAF-16 target genes to
promote animals’ health aging.
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Figure 3.5 RJ/eRJ depends on the interplay of DAF-16, SIR-2.1, HCF-1 and 143-3 to modulate C. elegans lifespan. C. elegans lead a regular lifespan when treated
with regular food (E. coli OP50), however, RJ/eRJ supplementation may trigger the
regulatory interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 to fine-tune DAF-16
activity in the nucleus autonomously. This sophisticated modulation induces a series of
DAF-16 target genes expressions to extend C. elegans lifespan.
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At the beginning, wild type worms were treated with different concentrations of
RJ/eRJ, ranging from 0 to 5 mg/mL, to select an optimum concentration for lifespan
extension by comparing their mean lifespans. The lowest concentration (0.4 mg/mL) and
highest concentration (5mg/mL) barely influenced mean lifespan of wild type worms, but
the concentration of 1 to 3 mg/mL RJ/eRJ extended C. elegans lifespan significantly. Our
results indicated that RJ/eRJ extended C. elegans lifespan in a dose dependent manner. In
consideration that Royal Jelly is composed of 67% water, 12.5% crude protein, 11%
simple sugars, and a relatively high amount (5%) of fatty acids[154], it is conceivable
that the effective pro-longevity factors are included in proteins and fatty acids parts.
Therefore the lower concentration (0.4 mg/mL) does not contain enough functional
proteins to prolong worms’ mean lifespan. In contrast, even the 5mg/mL Royal Jelly
includes high concentration of proteins and fatty acid, the results showed that the
5mg/mL Royal Jelly shortened worms’ lifespan. It is well known that many natural
substances used for therapeutic benefit have the potential to have their benefits eclipsed
by toxic effects at high doses[155]. Morever, it is reported that high concentration of
sugar could shorten worms’ lifespan. In agreement with this, we realized that the 5
mg/mL RJ/eRJ contains nearly 1mg/mL sugar, which might be the reason that higher
concentration of RJ/eRJ cannot prolong the lifespan.
Next, we wondered whether there is any difference of anti-aging effect between
the two types of Royal Jelly powders in our research. The manufacturing process of the
two powders are almost the same: after the filtration, disinfection, lyophilization, and
pulverization steps, fresh Royal Jelly is processed to powder, which makes Royal Jelly
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easy to be stored and utilized in experiments. The only difference between the two types
of Royal Jelly is the proteases treatment, which decomposes large proteins into amino
acids and peptides. The aim of this enzyme treatment is to decrease the large-proteins
induced allergic properties but still retain bioactive functions. In order to prepare the
RJ/eRJ paltes, the RJ/eRJ powders were dissolved in sterile distilled water and vortex
vigorously to dissolve adequately. Noticeably, a lot of floating bubbles were observed on
the surface of RJ powder mixture, but this phenomenon was not observed in eRJ mixture,
which indicated that the composition of RJ and eRJ were different and the bubbles in RJ
might be cause by certain large proteins. Intriguingly, our lifespan results showed that
both RJ and eRJ increased C. elegans lifespan, but the optimum concentrations of RJ and
eRJ were different (2mg/mL RJ and 1mg/mL eRJ, respectively) (figure 3.1 and table 1).
This finding suggested that the enzyme digestion might decrease the toxicity of certain
RJ and, in turn, alter bioactivity and improve the immune system of C. elegans. As a
result, the optimized concentration of eRJ for lifespan extension is reduced to 1mg/mL,
only half of RJ concentration. However, there is also a problem cannot be ignored,
although the enzyme treatment decreased the large-proteins induced allergic response in
eRJ supplementation, the mean lifespan of 2mg/ml RJ (15.52 days) was 1.08 days longer
than 1mg/mL eRJ treatment(14.44 days). This data demonstrated that certain large RJ
proteins, which were deleted by protease in eRJ powder, might have the beneficial effects
in anti-aging function. Further experiments need to be conducted to investigate the
differences between RJ and eRJ’s pro-longevity effects.

62

Overall, our lifespan results indicated that RJ/eRJ extended C. elegans lifespan in
a dose dependent manner, and the optimum concentrations of lifespan extension were
determined to be: 2mg/mL RJ and 1mg/mL eRJ, which were used in the further
experiments to investigate the molecular mechanism underlying this beneficial effect.
Moreover, RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) did not affect worms’
physiological indexes, such as reproductive capacity and mobility, which indicated that
RJ/eRJ was safe to be consumed as a functional product. Therefore, it is possible that
RJ/eRJ might be a beneficial nutraceutical for human consumption because of its lifespan
extension function and safety.
Given that RJ/eRJ extended C. elegans lifespan, we further investigated the
molecular mechanism underlying this beneficial effect. It is well known that Insulin Like
Signaling pathway (IIS) is a master regulator of longevity, and DAF-16 was an important
component at downstream of IIS pathway. Honda’s research group published that
IIS/DAF-16 was required in Royal Jelly’s anti-aging function. In agreement with their
study, our genetic results also showed that IIS/DAF-16 was critical in RJ/eRJ’s anti-aging
function, because both RJ/eRJ cannot extend the mean lifespan of daf-2 deletion mutants,
age-1 deletion mutants and daf-16 deletion mutants’ lifespan respectively (Figure 3.3).
As an important transcriptional factor of IIS, DAF-16 plays a key role in regulating
proliferation, metabolism, and longevity. Morever, DAF-16’s activity is known to be
regulated by post-translational modifications, nuclear/cytoplasmic translocation and is
also associated with transcriptional co-factors[156]. We further investigated whether
RJ/eRJ mediated lifespan extension was dependent on modulating the activity of DAF-16.
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Previous studies have demonstrated that reduction of IIS activates DAF-16 by
increasing its nuclear translocation to extend lifespan. Our genetic results suggested that
RJ/eRJ mediated lifespan extension, at least in part, acted through IIS pathway. This
finding indicated that under the supplementation of RJ/eRJ, increased amount of DAF-16
might translocate into the nuclear. Unfortunately, we did not observe the florescence
signal in RJ/eRJ treated DAF-16:GFP worms, indicating that RJ/eRJ barely affected
DAF-16 nuclear translocation. There are two possibilities to explain this result. First, it
has been reported that many obvious DAF-16 nuclear translocations are caused by severe
stresses or the alteration of crucial genes alteration. In comparison, Royal Jelly is a
functional food and induces mild changes in C. elegans growth process, which are similar
to a normal physiological level. As a result, this moderation increases of DAF-16 nucleus
translocation is not strong enough to be observed under regular fluorescence microscopy.
Another possibility is RJ/eRJ increases the transactivity of DAF-16 rather than promoting
DAF-16’s nucleus translocation. It is well known that DAF-16 nucleus translocation is
very important for DAF-16 activation, but translocation of DAF-16 into nucleus is not
sufficient to stimulate its transcriptional activity. Therefore our hypothesis is that
although RJ/eRJ did not elevate DAF-16’s nuclear translocation amount, RJ/eRJ still
increased DAF-16 activity to modulate the expression of its target genes. Indeed, the
changes of DAF-16 target genes expressions are much more sensitive to be detected by
using quantitative PCR method. . Our quantitative PCR experiments showed that RJ/eRJ
did not change DAF-16 gene expression, but significantly influenced the expression of its
target genes (sod-3, mtl-1, F21F3.3 and C32H11.4). Specifically, the expression of sod-3
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and mtl-1 (two important biomarkers of DAF-16) were increased more than two folds in
RJ/eRJ treated worms. This result indicated that DAF-16 activity was up-regulated under
RJ/eRJ supplementation. Although the increased DAF-16 translocation is not detected in
our research, the DAF-16 target gene expression results confirmed that RJ/eRJ anti-aging
function acts through increasing the DAF-16 activity (Figure 3.3 E).
DAF-16/FOXO has been reported to play an essential role in regulating cell
proliferation and maintaining the energy homeostasis in organisms. DAF-16 activity is
tightly controlled by genes and pathways, the regulatory specificity and precision of
DAF-16 is critical to ensure several biological processes. It is reported that dysregulation
of FOXO1 could cause a series of diseases, such as hyperglycemia and glucose
intolerance[157]. As an important transcription factor, DAF-16 functions to regulate
many important biological processes by modulating expressions of many genes, and the
regulation of DAF-16’s activity depends on the balance of a complicated interplay among
several co-factors. It is reported that SIR-2.1, HCF-1 and 14-3-3, three important DAF-16
co-factors, have physical interactions with DAF-16 to modulate its activity. Berdichevsky
and his colleagues reported that under heat shock stress, 14-3-3 functioned as a bridging
protein to link SIR-2.1 with DAF-16, this interplay induced the expression of DAF-16
target genes and thereby extended the survival of C. elegans under stress[48]. Another
important co-factor is HCF-1, which plays a key role in transcriptional processes and cell
cycle control. Li and colleagues reported that HCF-1 is also a putative longevity
determinant factor to modulate DAF-16 activity, independently from IIS. Their findings
revealed that the reduction of HCF-1 increased DAF-16 activity to extend lifespan[49].
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Moreover, their follow-up research suggested under the reduction of IIS, HCF-1, SIR-2.1,
and 14-3-3 proteins might modulate DAF-16 activity in the nucleus to respond to aging
and stress[65]. In our study, the results provided more evidence to confirm their results
and underscored the significance of these four proteins regulatory interplays in dietary
aging intervention. Our genetic results showed that besides IIS/DAF-116, DAF-16 cofactors- SIR-2.1, 14-3-3, and HCF-1- were also required to modulate DAF-16 activity in
RJ/eRJ mediated aging intervention. Additionally, the quantitative PCR results showed
that RJ/eRJ did not affect the expression of sir-2.1 and hcf-1 genes. In considering that
overexpression of SIR-2.1 and down-regulation of HCF-1 could increase the C. elegans
lifespan respectively, our results indicated that RJ/eRJ mediated pro-longevity effects
were dependent on promoting the interplays of SIR-2.1, HCF-1, and DAF-16 to modulate
the transactivity of DAF-16 rather than influencing the expression of hcf-1 and sir-2.1.
Moreover, the expression of C32H11.4 and F21F3.3 (target genes of both HCF-1 and
DAF-16[49]) in C. elegans were changed by RJ/eRJ supplementation, which further
confirmed our genetic data that DAF-16 and its co-factors were required in RJ/eRJ
mediated aging intervention.
Numerous studies have demonstrated that Royal Jelly is a functional nutraceutical
and has many beneficial effects, such as anti-fatigue effects, stimulates bone formation,
regulates immune responses, and protects liver from virus induced damage in animal
models[99-101, 158] In honey bees, genetically identical honey bee larvae develop into
either worker bees or queen bees depending on exposure to Royal Jelly. Based on the
composition of Royal Jelly, nearly half dry mass of Royal Jelly is protein, which might
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be the most powerful regulator to determine a honey bee’s fate and lifespan. It is possible
that Royal Jelly function proteins might be beneficial to other animals through food
intake. Our research highlights the pro-longevity properties of RJ and reveals the
molecular mechanism of Royal Jelly’s beneficial effects, which might also be applied to
mammal systems, including humans. It is conceivable that Royal Jelly supplementation
functions as aging-intervention method for humans to promote healthy aging and delay
the age-related disorders, further clinical research remains to be conducted to confirm our
hypothesis.
It is well known that IIS pathway, DAF-16/FOXOs, SIR-2.1/SIRT1, HCF-1 and
14-3-3 are evolutionarily conserved from C. elegans to mammals, our RJ/eRJ
supplementary C. elegans model might be implicated mammal models to further study
the genetic network of aging. In addition to SIR-2.1, HCF-1 and 14-3-3, other DAF-16
co-factors might also involve in the RJ/eRJ mediated pro-longevity function, for example,
SMK-1, BAR-1, et al[47, 159]. Moreover, besides IIS pathway, other pathways might
also be required in Royal Jelly mediated beneficial effects, such as JNK pathway, TOR
pathway, and P38 MAPK pathway [160-162]. Further research will be carried out in the
future to help us better understand the detailed mechanism of aging process.
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CHAPTER FOUR : THE ANTI-STRESS CAPABILITY OF ROYAL JELLY
SUPPLEMENTATION
4.1 Introduction

In Chapter three, our results demonstrated that RJ/eRJ extended C. elegans
lifespan without affecting the physiological indexes. This beneficial effect acted through
IIS/DAF-16 and its three important co-factors, SIR-2.1, HCF-1, and 14-3-3, which are
essential proteins to regulate metabolism, proliferation, and longevity in C. elegans.
Cumulative evidence indicated that the lifespan extension benefits are often correlated
with increased stress resistant capability[163, 164]. Interestingly, our quantitative PCR
results showed that the supplementation of Royal Jelly could affect the expression levels
of certain stress response genes, such as sod-3, mtl-1, C32H11.4, and F21F3.3. Moreover,
DAF-16 regulates numerous stress response genes, such as anti-oxidant and protein
turnover genes, to maintain the protein homeostasis in cells. In addition to DAF-16, its
three co-factors, SIR-2.1, HCF-1, and 14-3-3 are also reported to be involved in stress
response and adaptions. It is highly possible that RJ/eRJ supplementation might also have
anti-stress functions. In order to confirm this hypothesis, stress assays were conducted to
investigate whether RJ/eRJ could protect C. elegans from a variety of stressors, including
oxidative stress, UV irradiation, and heat shock stress.
Environmental stresses and normal cell metabolism could form Reactive Oxygen
Species (ROS), which may result in significant damage to cell components[165]. In
response to this damage, cells are equipped with internal protective systems, such as
antioxidant molecules, DNA repair pathways, and chaperones, to repair the destructed
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DNA and proteins to maintain cellular homeostasis[166]. However, under persisting
stress conditions or in the aging cells, the oxidative damages are accumulated, and the
cells’ repair capacity is declined, which in turn increases cellular proteotoxicity to
accelerate the aging process and cause several diseases, such as neurodegenerative
diseases, cancer, and premature aging[149].
Several labs have demonstrated that some nutraceuticals have pro-longevity effect
as well as stress resistance capacity. For example, resveratrol could affect SIR2.1/SIRT1’s activity to extend lifespan and increase resistance to oxidative stress and UV
irradiation in animal models[96]. Similarly, cranberry influenced Insulin Signaling
Pathway to protect C. elegans from thermal stress and slow down the aging process[123].
Our research revealed that RJ/eRJ also had the anti-stress functions to protect C. elegans
from oxidative stress, UV irradiation and heat shock. Moreover, this stress resistance
beneficial effect was dependent on, at least in part, the regulation of DAF-16, SIR-2.1,
HCF-1, and 14-3-3.
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4.2 Results
4.2.1 Supplementation of RJ/eRJ promotes C. elegans stress resistance to
oxidative stress, UV irradiation, and heat shock stress

Extended longevity is often genetically correlated with increased resistance
against various stressors, including oxidative stress, heat shock, UV irradiation, osmosis
stress, and pathogen infection. In chapter three, we demonstrated that RJ/eRJ
supplementation had lifespan extension benefit. Herein, we want to investigate whether
RJ/eRJ supplementation could protect worms against stresses.
First of all, oxidative stress was tested to investigate whether RJ/eRJ could protect
C. elegans from oxidative damages. Wild type worms (N2) were treated with or without
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for two generations (5 days) under
25°C. Then the synchronized L4/young adult worms were transferred to NGM plates
containing 5mM paraquat to observe survival. Basically, paraquat is an organic
compound which can produces superoxide anions to induce redox activity. In our
research, paraquat was used to create oxidative stress environment. At the same time, N2
worms treated with or without RJ/eRJ on regular NGM plates (no paraquat) were set as a
system control.
Based on our observation, on the second day, the survival rate of controls was
lower than 80%, whereas nearly 98% of RJ/eRJ treated worms were still alive. On the
fourth day, more than 50% of control worms were already dead, but the RJ/eRJ treated
worms’ survival rate was more than 80%. Surprisingly, on the sixth day, the survival rate
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of RJ/eRJ treatment was more than two times longer than the survival rate of the controls.
This experiment was continued until day 10, and the data was analyzed to compare the
differences between each treatment (Figure 4.1 A and B). This result indicated that
RJ/eRJ could protect C. elegans from oxidative stress.
Next, UV irradiation stress was tested to study whether RJ/eRJ could protect C.
elegans from UV-light induced DNA damage. C. elegans were treated with or without
RJ/eRJ for two generations before exposure under UV irradiation at 0.05J/cm2 for 20
seconds. After treated with UV irradiation, C. elegans were cultured at 25°C to observe
survival for 10 days. Meanwhile, N2 worms treated with or without RJ/eRJ on regular
NGM lifespan plates (no UV irradiation) were set up as a system control to check
whether the whole system works well. The UV irradiation result showed that on the
second day, the survival rate of control group was lower than 80%, whereas nearly 98%
RJ/eRJ treated worms were still alive. On the fourth day, the survival rate of control
group dropped to nearly 50%; by contrast, the RJ/eRJ treated worms survival rate was
still 80%. Noticeably, on the sixth day, only less than 20% of control worms were still
alive, and the RJ/eRJ treated worms survival rate was around two to three times higher
when compared with the rate of the control group (Figure 4.1 C and D). This result
suggested that RJ/eRJ supplementation increased C. elegans UV irradiation resistance.
Heat shock stress was tested to investigate whether RJ/eRJ could protect C.
elegans from thermal-induced proteins damage. Worms were treated with or without
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for two generations at 25°C (5 days).
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Then the synchronized L4/young adult worms were heat shocked for three hours at 35°C
and returned back to 25°C. Survivals were observed for ten days to compare the
difference of each treatment. Meanwhile, N2 worms treated with or without RJ/eRJ on
NGM lifespan plates (no heat shock) were set up as a system control. On the second day,
more than 70% of the heat shocked control worms were dead, but the RJ/eRJ worms’
survival rates were more than 80% (in RJ treatment heat shocked) and 60% (in eRJ
treatment heat shocked). On the fourth day, the survival rate of heat shocked control
worms was less than 30%, while the survivals of RJ/eRJ treated worms were nearly two
to three fold higher comparing with that of the control group. Interestingly, the results of
day 6, 8 and 10 showed the same trend that RJ/eRJ treated worms survival percentages
were higher than those of the control group (Figure 4.1 E and F). This result
demonstrated that RJ/eRJ protected C. elegans against heat shock stress.
Taken together, our anti-stress assays indicated that RJ/eRJ supplementation
protected C. elegans against oxidative stress, UV irradiation, and heat shock stress.
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Figure 4.1 The RJ/eRJ treatment results in a promoted stress resistance to
specific environmental stimuli. (A) The RJ (2mg/mL) treated N2 worms showed
prolonged survival in response to 5mM paraquat compared with non-treated worms. (B)
The eRJ (1mg/mL) treated N2 worms showed prolonged survival in response to 5mM
paraquat compared with non-treated worms. (C) The RJ (2mg/mL) treated N2 worms
showed elevated survival after ultraviolet (UV) irradiation compared with non-treated
worms. (D) The eRJ (1mg/mL) treated N2 worms showed elevated survival after UV
irradiation compared with non-treated worms. (E) The RJ (2mg/mL) treated N2 worms
exhibited increased survival after 3 hours at 35°C compared with non-treated worms. (F)
The eRJ (1mg/mL) treated N2 worms exhibited increased survival after 3 hours at 35°C
compared with non-treated worms. Each stress assay was repeated at least three times.
“Fraction alive” indicates the average survival among the multi-replicates and error bars
represent the standard deviation. p value was calculated using Student’s t test. *p < .05
compared with corresponding control. Each of the stress assays was repeated at least
three independent times with similar results.
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4.2.2 RJ/eRJ may promote stress resistance of C. elegans through, at least in part,
modulating the interplays of DAF-16, SIR-2.1, HCF-1, and 14-3-3 proteins

Given that the molecular mechanisms behind lifespan elongation and stress
resistance may not overlap, we questioned whether this RJ/eRJ mediated stress tolerance
may also require, at least partially, the interplays of DAF-16, SIR-2.1, HCF-1 and 14-3-3
proteins.
In this study, we treated the four mutant worms, daf-16 (mgDf50), sir-2.1 (ok434),
hcf-1 (ok599), and ftt-2 (n4426) with or without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ,
respectively) for two generations. Then mutant worms were exposed to oxidative stress,
UV irradiation, and heat shock stress to observe their stress resistant capability. The
differences in survival rates were compared between RJ and eRJ treatments with controls
in each stress response to analyze whether RJ/eRJ mediated stress responses share the
same genetic mechanism with its pro-longevity function.
In the oxidative stress experiment, RJ/eRJ cannot protect four mutant worms
under paraquat treatment, which indicated that DAF-16, SIR-2.1, HCF-1, and 14-3-3
were required in RJ/eRJ mediated anti-oxidative stress response. Interestingly, it is worth
noting that the p value of RJ/eRJ treatment versus control group in daf-16 (mgDf50) and
hcf-1 (ok599) were just beyond the statistical significance (p<0.05), but very close to it
(Table 5). These data indicated that, besides DAF-16, other transcriptional factors might
also be required in RJ/eRJ mediated anti-oxidative stress.
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In the UV irradiation stress assays, our data showed that RJ/eRJ cannot protect
daf-16 (mgDf50) and sir-2.1 (ok434) mutant worms against UV irradiation, but RJ/eRJ
can still increase the survival rate of hcf-1 (ok599) and ftt-2 (n4426) mutant worms (Table
5), which indicated that RJ/eRJ required DAF-16 and SIR-2.1, but not HCF-1 and 14-3-3
to protect C. elegans against UV irradiation stress.
In the heat shock stress assays, our results showed that DAF-16, SIR-2.1 and 143-3 were involved in RJ/eRJ mediated anti-heat shock stress. However, HCF-1 was not
required because RJ/eRJ can still protect hcf-1 (ok599) mutant worms from heat shock
stress. Intriguingly, there is a problem cannot be ignored, the p values of RJ/eRJ
treatment versus non-treatment controls in daf-16 (mgDf50) and sir-2.1 (ok434) mutant
worms were just beyond the statistical significance (p<0.05), but very close to it (Table 5).
These data also implied that besides DAF-16, other regulators might also be required in
RJ/eRJ mediated heat shock stress responses.
Overall, our findings suggested that RJ/eRJ may promote stress resistance of C.
elegans through, at least partially, modulating the interplays of DAF-16, SIR-2.1, HCF-1,
and 14-3-3 proteins.
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Table 5. The Survival Time of Various Worm Strains under Stresses

Oxidative
Stress

No.of
worms
73
72
75

strain
daf-16 (mgDf50)
daf-16 (mgDf50) + 2mg/mL RJ
daf-16 (mgDf50) + 1mg/mL eRJ

Mean±SE Median
3.10±0.16
3.00
3.43±0.19
3.00
3.40±0.18
3.00

sir-2.1 (ok434)
sir-2.1 (ok434) + 2mg/mL RJ
sir-2.1 (ok434) + 1mg/mL eRJ

3.73±0.22
3.96±0.24
3.72±0.21

4.00
4.00
4.00

70
74
75

0.471
0.927

hcf-1(ok559)
hcf-1(ok559) + 2mg/mL RJ
hcf-1(ok559) + 1mg/mL eRJ

5.95±0.29
6.92±0.31
6.93±0.29

6.00
7.00
7.00

83
76
75

0.055
0.057

ftt-2 (n4426)
ftt-2 (n4426) + 2mg/mL RJ
ftt-2 (n4426) + 1mg/mL eRJ

3.77±0.24
4.00±0.24
4.25±0.26

4.00
4.00
4.00

68
84
73

0.399
0.186

2.94±0.66
3.17±0.08
3.18±0.09

3.00
3.00
3.00

63
86
76

0.177
0.181

sir-2.1 (ok434)
sir-2.1 (ok434) + 2mg/mL RJ
sir-2.1 (ok434) + 1mg/mL eRJ

3.57±0.11
3.67±0.11
3.77±0.13

4.00
4.00
4.00

74
78
74

0.474
0.138

hcf-1(ok559)
hcf-1(ok559) + 2mg/mL RJ
hcf-1(ok559) + 1mg/mL eRJ

5.07±0.29
6.28±0.28
6.02±0.32

5.00
6.00
6.00

86
104
89

0.012
0.039

ftt-2 (n4426)
ftt-2 (n4426) + 2mg/mL RJ
ftt-2 (n4426) + 1mg/mL eRJ

4.64±0.27
5.68±0.32
5.75±0.30

4.00
5.00
5.00

67
56
56

0.022
0.016

Ultraviolet daf-16 (mgDf50)
Irradiation daf-16 (mgDf50) + 2mg/mL RJ
daf-16 (mgDf50) + 1mg/mL eRJ
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p value
0.050
0.051

Table 5 (continued). The Survival Time of Various Worm Strains under Stresses

Heat
Shock

strain
daf-16 (mgDf50)
daf-16 (mgDf50) + 2mg/mL RJ
daf-16 (mgDf50) + 1mg/mL eRJ
sir-2.1 (ok434)
sir-2.1 (ok434) + 2mg/mL RJ
sir-2.1 (ok434) + 1mg/mL eRJ
hcf-1(ok559)
hcf-1(ok559) + 2mg/mL RJ
hcf-1(ok559) + 1mg/mL eRJ
ftt-2 (n4426)
ftt-2 (n4426) + 2mg/mL RJ
ftt-2 (n4426) + 1mg/mL eRJ

Mean±SE
2.63±0.11
2.95±0.12
2.97±0.16
3.35±0.31
4.35±0.37
4.19±0.34
4.25±0.36
5.76±0.38
5.55±0.39
3.64±0.37
4.36±0.40
3.89±0.33

Median
3.00
3.00
3.00
3.00
4.00
4.00
4.00
6.00
6.00
4.00
4.00
4.00

No.of worms
111
87
68
83
69
74
94
70
78
72
81
94

p value
0.062
0.063
0.051
0.054
0.035
0.046
0.166
0.782

Notes: The life span and standard error were shown in days. The life-span experiments
were repeated at least three times with similar results, and the data for representative
experiments were shown. The life-span data were analyzed using the log-rank test
and p values for each individual experiment are shown. SE = standard error.
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4.3 Discussions

Numerous studies showed that lifespan extension is often correlated with
increased stress resistance[167]. Genetic manipulations in Insulin Signaling Pathways as
well as feeding and dietary restrictions affected lifespan and stress resistance significantly.
For instance, the deletion of daf-2 were found to double the lifespan of wild type worms
and resistant to several stressors, such as oxidative and thermal stresses[168]. Another
example of this genetic manipulation is eat-2 deletion mutant, which has a feeding
problem during growth and has also showed long-lived and anti-stress phenotypes.
However, the molecular mechanism underlying the link between pro-longevity and stress
resistance is still unclear. One possible reason might be that some pro-longevity factors
not only have the lifespan extension function but also protect organisms from the
damages caused by stresses.
In our daily life, we are always exposed to complex mixtures of various
environmental pollutants, which are produced by natural and human made sources such
as combustion, construction, agriculture and so on. Some chemicals or pollutants could
cause toxic effects to impair human’s health. The accumulation of these damages could
accelerate the aging process and increase the risk of cancer, diabetes, obesity, and
neurodegenerative diseases. Several pieces of evidence hint that there might be a link
between aging, stress, and age-related diseases[169].
Several aging research labs revealed that some functional nutraceuticals had antistress function. Ungvari and Jin published that resveratrol, a popular pro-longevity
product, had the antioxidant effect and thereby alleviated Parkinson’s disease[170].
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Moreover, Guha and Guo reported that cranberry, a healthy fruit, possessed the heat
shock resistant capability as well as lifespan extension. Moreover, it can delay the onset
development of Alzheimer’s disease[123]. In addition, numerous publications reported
that nutraceuticals have lifespan extension and stress resistance, which further confirmed
the link between pro-longevity and anti-stress functions.
In chapter three, our results demonstrated that RJ/eRJ had pro-longevity function
and explained the molecular mechanism underlying this beneficial effect. Noticeably, our
quantitative PCR results showed that RJ/eRJ regulated DAF-16 activity by affecting
expressions of its target genes: sod-3, mtl-1, C32H11.4, and F21F3.3. Moreover, the
elevated expressions of sod-3, mtl-1, F21F3.3, and repressed expression of C32H11.4
indicated that RJ/eRJ might promote C. elegans stress resistance ability.
The sod-3 gene, part of the SODs protein family that encodes an iron/manganese
superoxide dismutase in mitochondrial, was found to be an anti-oxidant gene in C.
elegans and conserved in mammals[171]. SODs are anti-oxidant enzymes that transfer
superoxide radicals into hydrogen peroxide and oxygen. The mlt-1 gene encodes one of
two C. elegans metalliothioneins and plays an important role in homeostasis and
detoxification. It was discovered that the expression of intestinal mtl-1 gene was upregulated when worms were exposed to cadimium and heat shock[172]. It is possible that
mtl-1 functions as an essential protector in oxidative stress, DNA damage, and heat shock
stress. In addition to sod-3 and mtl-1, the expression of F21F3.3 was also up-regulated in
RJ/eRJ treatment. Previous research revealed that F21F3.3 functions as a
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methyltransferase to regulate protein folding and localization during the protein quality
control process in the endoplasmic reticulum. Moreover, F21F3.3 was regulated by both
DAF-16 and HCF-1 and may play a role in stress resistance[49]. C32H11.4 is one of a
CUB-like protein, and its expression level was down-regulated in RJ/eRJ treated worms.
Given that CUB-like proteins could affect the arsenate induced stress resistance and
immune response[80], it is conceivable RJ/eRJ supplementation might strengthen worms’
immune system and protect them against certain stresses. Based on these quantitative
PCR results, we speculated that RJ/eRJ might protect worms from stresses through
regulating the expression of DAF-16 related stress resistant genes. In order to confirm our
hypothesis, we did oxidative stress, UV irradiation, and heat shock stress assays to check
whether RJ/eRJ has the anti-stress ability.
First, we tested whether RJ/eRJ supplementation could protect C. elegans against
oxidative stress. It is well known that oxidative stress is unavoidable and caused by the
production of reactive oxygen species (ROS) from cellular mitochondrial respiration,
which impairs a series of essential cellular components such as proteins, lipids, and DNA.
In order to protect organisms from these damages, cells could produce superoxide
dismutase (SOD), catalase, and glutathione peroxidases to transform the ROS to less
toxic forms, which in turn detoxify the reactive intermediates and repair the cellular
damages[165]. However, the balance of reactive oxygen production and consumption can
be destroyed under certain conditions, such as persisting exogenous stress or in aging
cells. When cells themselves cannot remove or degrade ROS efficiently, the
accumulation of cellular damages will cause disease and accelerate the process of aging.
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In our research, paraquat was used to mimic the oxidative stress conditions by
producing a large amount of superoxide. Worms were treated with or without RJ/eRJ for
two generations before being exposed to paraquat. Survival rates were observed to
compare the differences in each treatment. Our results showed that both RJ and eRJ could
protect C. elegans from paraquat induced oxidative stress and that there was no
difference between RJ and eRJ’s anti-oxidant ability (Figure 4.1). Moreover, further
results showed that DAF-16, SIR-2.1, HCF-1, and 14-3-3 were required in this antioxidant response (Table 5). Noticeably, the p value of RJ/eRJ treatment versus that of the
control group in daf-16 (mgDf50) and hcf-1 (ok599) mutants were just beyond the
statistical significance (p<0.05) but very close to it. However, it is worth noting that in
N2 worms’ oxidative stress experiment, the mean lifespan of RJ/eRJ treated worms were
7 days and 6 days respectively when compared with the mean lifespan of control (4 days)
(Figure 4.1). This result demonstrated that RJ/eRJ supplementation increased survival of
N2 worms under paraquat induced oxidative stress by 50%. Although the p value of
RJ/eRJ treated daf-16 (mgDf50) and hcf-1 (ok599) versus non-supplemented genetically
matched mutants was close to 0.05, RJ/eRJ only increased survival of daf-16 (mgDf50)
mutants by 10.65% and survival of hcf-1 (ok599) mutants by 16.30% (Table 5). These
data suggested that DAF-16 and HCF-1 also played a very important role in RJ/eRJ
mediated oxidative response, and other regulators might also be required in this
beneficial effect.
Accumulated evidence demonstrated that in addition to DAF-16, SKN-1, BAR-1,
and SMK-1 were also important regulators in oxidative stress resistance[173, 174].
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Similar to DAF-16, SKN-1 is also a transcriptional factor downstream of IIS pathway,
that has elevated expression in intestinal nuclei under stress or reduced IIS signaling.
Additionally, SKN-1 modulates a set of downstream genes, which contribute to
detoxification, cellular repair, and pathogen resistance[40]. SKN-1 is also regulated by
P38 MAPK pathway to modulate oxidative stress tolerance[175]. Our results showed that
RJ/eRJ supplementation altered the expression of C32H11.4, and it is well known that
C32H11.4 is regulated by both DAF-16 and SKN-1 under stresses. SKN-1 may be
involved in RJ/eRJ mediated anti-oxidative stress response. Another possible factor is βcatenin BAR-1, a DAF-16/FOXO co-factor, which can directly bind to FOXO to enhance
its transcriptional activity in mammals. Essers and colleagues published that the interplay
between BAR-1 and FOXOs was increased under oxidative stress[173]. Moreover, BAR1 was required for the expression DAF-16 target gene sod-3 in response to oxidative
stress. Our results showed that RJ/eRJ increased the gene expression of sod-3
approximately two fold, which raised the possibility that BAR-1 might be required in
RJ/eRJ mediated anti-oxidative response. Additionally, SMK-1, another essential
regulator of DAF-16, could also influence DAF-16 associated anti-aging effects by
modulating DAF-16 transcriptional activity. Dillin’s lab reported that SMK-1 was
involved in several DAF-16 associated functions, such as UV irradiation, innate
immunity, and oxidative stress response[47]. Further experiments are needed to
investigate whether SKN-1, BAR-1, and SMK-1 are required in RJ/eRJ dependent antioxidant response; this information would greatly advance our understanding of the
mechanistic details of oxidative stress.
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In addition to IIS pathway and DAF-16, the well-studied but controversial sirtuin
pathway was also required in RJ/eRJ mediated anti-oxidative stress (Table 5). To date,
cumulative publications claim that SIR-2.1/SIRT1 plays a key role in the anti-oxidant
response, but the precise role of SIR-2.1/SIRT1 is still unclear[176]. Sirtuin enzymes are
a conserved family of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases
and ADP-ribosyl-transferases, which regulate lifespan extension and stress resistance
under dietary restriction. In a study of mammals, SIRT1 was shown to deacetylate and
activate FOXOs (FOXO1, FOXO3a, and FOXO4) and promote the production of DNA
repair factor[177]. Moreover, under modification of ROS, SIRT1 could activate P53 to
reduce cellular apoptosis and promote peroxisome proliferator activated receptor gamma
coactivator 1 α (PGC-1 α) to produce mitochondrial antioxidant enzyme manganese
superoxide dismutase (MnSOD) in response to oxidative stress[178]. However, there are
numerous contradictory results in sirtuin research, and the precise role of SIRT1
mediated oxidative resistance is still elusive. Our study revealed that SIR-2.1 was
required in RJ/eRJ mediated anti-oxidant response; therefore RJ/eRJ treatment could be
utilized as a model to further investigate the detailed molecular mechanism of SIR-2.1
regulation in response to oxidative stress.
Paraquat, a common herbicide, not only induces an oxidative stress but also
causes toxic effect to animals[179]. In our oxidative stress assay, worms’ mean lifespan
was decreased from 12 days to 4 days because of the toxicity induced by the paraquat
treatment (Figure 4.1). This result demonstrated that paraquat significantly shortened C.
elegans lifespan because of its toxicity. Similarly, paraquat is also harmful to humans. In
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2011, a U.S. National Institutes of Health study reported that farm workers were at a high
risk for Parkinson’s disease because of their frequent usage of paraquat[180].
Furthermore, other studies revealed that the accumulation of oxidizing species caused by
paraquat exposure could destroy cell structure and protein function, leading to the
development of Parkinson’s disease in humans[181]. In addition to Parkinson’s disease,
oxidative stress could also increase the risk of other age-related diseases such as cancer,
Alzheimer’s disease, atherosclerosis, heart failure, and chronic fatigue syndrome[182].
Collectively, our results indicated that RJ/eRJ not only protected worms from
oxidative stress, but also alleviated paraquat induced toxicity. It is possible that RJ/eRJ
might protect C. elegans against cytotoxicity and we will discuss this beneficial effect in
the next chapter.
It is well known that ROS is a major inducer of oxidative stress, but recent studies
reported that ROS are not always harmful. Hamanaka and Chandel demonstrated that
ROS also participates in cell signaling to regulate a variety of biological processes[165].
Moreover, several pathways could be activated by a short term of mild oxidative stress,
which is beneficial for the immune system to kill pathogens and in turn lead a healthy
aging. In 2008, Gems and Partridge published a theory of “mitohormesis,” which
demonstrated that a low dose of stress could stimulate immunity to fight against
pathogens and harmful effects to slow down the aging process[183]. It is possible that
RJ/eRJ treatment might mimic the mild stress to strengthen the immune system and
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DAF-16 transcriptional activity of C. elegans to promote lifespan extension and oxidative
stress resistance.
Next, we investigated whether RJ/eRJ could protect worms from DNA damage to
maintain genome integrity. Based on our knowledge, cells maintain a good balance
between ROS production and antioxidant defenses in normal conditions; however,
dysregulation in this maintenance could cause mutations and cell death by high level
accumulative oxidant damages to DNA[112]. In humans, a lot of environmental factors
are known to induce DNA damages, such as solar UV irradiation, cigarette smoke, toxin,
chemotherapeutics, and food contained chemicals. The unrepaired DNA damages could
accelerate the aging process and increase the risk of cancers. In order to solve this
problem, more and more scientists focus on investigating the molecular mechanisms of
DNA damages and looking for effective treatment to prevent relative diseases[169].
Given that reduced oxidative damages might be correlated with increased genome
integrity, it is possible that RJ/eRJ might also help C. elegans in DNA damage response.
In order to confirm this hypothesis, UV irradiation experiment was carried out to observe
worms’ survival rate under RJ/eRJ supplementation and non-supplemented controls. In
our study, UV irradiation was utilized to cause the formation of cyclobutane pyrimidine
dimers (CPDs) and 6-4-photoproducts (6-4 PPs), which substantially distort double helix
structure of DNA to induce DNA lesions in C. elegans.
Our N2 worms’ UV stress assay showed that RJ/eRJ prolonged the survival of N2
worms by 25% (RJ) and 50% (eRJ) under UV stress when compared with non-
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supplemented control worms (Figure 4.1). In order to investigate the molecular
mechanism underlying this protective function, daf-16 (mgDf50), sir-2.1 (ok434), hcf-1
(ok599), and 14-3-3 (n4426) mutant worms were exposed under UV irradiation with or
without pre-treatment of RJ/eRJ for two generations. Surprisingly, our results showed
that RJ/eRJ also increased the survival of hcf-1(ok599) mutants by 23.87% and the
survival of 14-3-3(n4426) mutants by 22.41%, and the p value of RJ/eRJ versus control
was less than 0.05. However, RJ/eRJ supplementation failed to increase the survival rate
of daf-16 (MgDf50) and sir-2.1 (ok434) worms (Talbe 5), which demonstrated that only
DAF-16 and SIR-2.1 were required in RJ/eRJ mediated UV stress resistance.
RJ/eRJ supplementation might provide us a good model to investigate the
molecular mechanism of DNA damage. A growing body of evidence indicated that there
is a link between aging and age-related diseases to the loss of DNA repair capacity; the
declined capacity of DNA repair resulted in accelerating the process of aging[114]. Our
results showed that RJ/eRJ served as a beneficial supplementation to extend C. elegans
lifespan as well as increase their resistance to UV stress, which correlates DNA repair
capacity with healthy aging. Previous publications have revealed that the C. elegans
mutant defective in IIS pathway lead a longer lifespan and higher DNA repair
capacity[177], possibly because the reduced IIS elevated heat shock proteins (HSPs)
expressions via increasing DAF-16 transcriptional activity. In the yeast model, it has been
proposed that HSP90 could interplays with Ssl2, the yeast homolog of XPB, to promote
enzymatic activities involved in repair of UV induced DNA lesions[184]. In a study of
mammals, Mostoslavsky’s lab reported that SIRT6 plays an important role in DNA
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damage repair and aging[185]. Although the detailed molecular basis of DNA repair
capacity is unclear, accumulating evidence indicated that heat shock proteins, IIS
pathway, and surtuin pathway might be involved in this process.
In addition to IIS and surtuin pathways, other DNA repair pathways might be also
involved in this RJ/eRJ mediated anti-DNA damage function. It is well known that cells
are equipped with several DNA repair machineries to protect genome integrity against
UV irradiation-induced cellular damage. The NER pathway, composed of numerous
repair factors, is a general DNA repair machinery and displays multiple functions to
repair many types of DNA damages, ranging from small base modification to double
strand breaks[113]. Hyun and Ahn claimed that xpa-1, a nucleotide excision repair gene
of C. elegans, was required in DNA repair response of IIS defective mutants[186]. This
finding indicated that there are some interplays between IIS and NER pathways in DNA
repair process. Moreover, it is reported that the mutations in human NER genes could
cause several UV sensitive hereditary disorders, such as cockayne syndrome, premature
aging, and neurodevelopmental problems, which underscored the relationship between
DNA damage and aging.
Our research provided a good model to investigate the molecular mechanism of
DNA damage response. Further studies are needed to determine whether IIS/DAF-16 and
SIR-2.1 interplay with DNA repair pathways in providing UV resistant benefits, which
could help us to develop the effective treatment for DNA damage-associated disorders,
such as cancer and premature aging[153].
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The last stress response tested in our research was heat shock stress. Heat stress,
also called thermal stress, is designed to treat organisms at a higher temperature than the
ideal body temperature for a certain period. During heat stress, high temperature could
cause damage to protein structure and function in some degree. In response to this stress,
the cellular internal repair system is activated to up-regulate the expressions of heat shock
proteins (HSPs) to repair or degrade the destructed proteins. As a master regulator to
control the quality of proteins, HSPs function as molecular chaperones and play a critical
role in protein folding and intracellular trafficking, additionally, and denatured proteins
repair in stress and aging conditions[117].
Numerous studies have shown that some nutraceuticals have anti-heat stress
functions. In a C. elegans model, it is reported that under thermal stress, the first larval
stage (L1) or early L2 stage worms were induced to enter a dauer stage, which showed
long lived phenotype and survival under harsh conditions. However, for the welldeveloped young adult worms, heat shock stress could shorten their lifespan and cause
reproductive problems. Numerous studies demonstrated that several antioxidant
compounds could alleviate this heat shock induced protein damage. For example, α-lipoic
acid and trolox, which were discovered as functional supplementation to increase C.
elegans lifespan and heat shock resistance. In our previous study, our results showed that
RJ/eRJ supplementation strengthened worms’ oxidative stress tolerance; thus it is highly
possible that RJ/eRJ may also have thermal stress resistance.
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In our study, wild type worms were pre-treated with RJ/eRJ for two generations
under 25°C. Then the synchronized young adult worms were heat shocked at 35°C for
three hours and returned back to 25°C to observe the survival of the worms receiving
different treatments. Our results showed that heat shock shortened the mean lifespan of
non-treated N2 worms from 12.97 days to 1.5 days. However, RJ/eRJ could increase
worms’ survival rate nearly 6 fold (RJ) and 3 fold (eRJ) when compared with the survival
rate of the controls (Figure 4.1). This result indicated that RJ/eRJ might protect C.
elegans from heat shock stress, possibly because that some bioactive factors in RJ/eRJ
could promote cells’ internal protein repair system to maintain protein structure and
function in response to heat shock stress.
Next, we compared the differences in thermal stress resistance in two types of
Royal Jelly treated worms. Noticeably, although both RJ and eRJ could protect C.
elegans from heat shock stress, the mean lifespan of heat shocked worms were
significantly different in these two treatments: the mean lifespan of RJ treatment was
around 9 days, whereas the eRJ treatment was only 4 days (Figure 4.1). This result
indicated that RJ’s anti-thermal stress function was much better than that of eRJ. As we
mentioned before in chapter three, the difference between RJ and eRJ was the enzyme
pre-treatment, which removed some large proteins to reduce the immune response in eRJ
powder. These removed large proteins might play an important role in heat shock
resistance by stimulating the immune system. Overall, our data suggested that besides
anti-oxidant and DNA repair capacity, RJ/eRJ also protected C. elegans from heat shock
stress.
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Next, we wondered whether DAF-16, SIR-2.1, HCF-1, and 14-3-3 are required in
RJ/eRJ mediated heat shock resistance. Herein, daf-16 (mgDf50), sir-2.1 (ok434), hcf-1
(ok599), and 14-3-3 (n4426) mutant worms were supplemented with or without RJ/eRJ
for two generations before being treated with heat shock stress. The results showed that
RJ/eRJ cannot prolong the survival of daf-16 (mgDf50), sir-2.1 (ok434), and 14-3-3
(n4426) mutant worms under heat shock stress, which indicated that except for HCF-1,
the other three proteins, DAF-16, SIR-2.1, and 14-3-3, were required in RJ/eRJ mediated
heat shock resistance. Noticeably, the p value of RJ/eRJ treated hcf-1 (ok599) versus
genetically matched controls was 0.046, less than the statistical significance. However,
RJ/eRJ only increased the hcf-1 (ok599) mutants worms’ mean lifespan by 1.31 fold
when compared with controls, which is far less than the increasing rate (6 fold in RJ and
3 fold in eRJ) of mean lifespan elongation in heat shocked N2 worms (Table 5). This data
indicated that HCF-1 was partially required in RJ/eRJ’s thermal stress resistance.
Numerous papers published that DAF-16 could protect cells from various stresses
by transcriptional up-regulation of its target stress response genes, especially heat shock
proteins. Our quantitative PCR results showed that RJ/eRJ treatment increased the
expression level of F21F3.3 (Figure 3.3), which functions in membrane proteins folding.
Besides F21F3.3, DAF-16 also regulates a series of protein-turnover genes. The majority
of these genes belong to heat shock protein (HSP) family, which modulate protein folding,
trafficking, aggregation, and degradation to maintain proteostasis[144]. As an essential
regulator to control protein quality, HSPs play a key role not only in normal conditions
but also in stress environments and aging cells. During the cell growth, HSPs guide the
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newly synthesized and misfolded proteins to fold into their correct and functional
conformations, and the well folded proteins are shuttled to the right place by chaperones
inside the cells. Moreover, the misfolded and unfolded proteins can be targeted by
ubiquitin, a small group of HSPs, and proteases for degradation. In addition to this
protein folding function, HSPs also served as a “cell monitor” to help the immune system
detect the infected cells by presenting pieces of proteins or antigens on the cell
surfaces[187]. Considering that our previous data showed that RJ/eRJ increased DAF-16
transcriptional activity, it is highly possible that RJ/eRJ could also promote the gene
expression levels of DAF-16 targeted heat shock proteins in heat shock resistance.
As shown above, in addition to DAF-16, SIR-2.1 and 14-3-3 were also required in
RJ/eRJ mediated heat shock tolerance; however, other factors, such as HSF-1, might also
be involved in this anti-heat stress function. The Guarente lab proposed a model to
explain the mechanism of heat shock stress: following the heat shock stress, SIR-2.1 can
bind and activate DAF-16 in a 14-3-3 dependent manner[48]. It is conceivable that
RJ/eRJ supplementation triggered the interplay of DAF-16, SIR-2.1, and 14-3-3 to
activate DAF-16 downstream stress resistant genes, and thereby protected C. elegans
from heat shock. However, it is worth noticing that in our mutant worms’ heat shock
stress data, the p value of RJ/eRJ treated daf-16 (mgDf50) and sir-2.1 (ok434) versus their
genetically matched control was 0.062 and 0.054 respectively, which indicated that
besides DAF-16 and SIR-2.1, other factors might also be involved in this anti-heat shock
resistance. It is highly possible that heat shock factor (HSF-1) is involved in this antistress effect. As same as DAF-16, HSF-1 is also an important transcriptional factor
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located at the downstream of IIS, and it is well known that DAF-16 and HSF-1 could act
together to turn on a specific subset of genes to promote longevity[37]. Moreover,
Morimoto’s lab claimed that SIRT1 deacetylated HSF-1 to up-regulate its target gene
HSP70 expression in mammals study. As an important HSPs, HSP70 not only assist in
the establishment of proper protein conformation, but also presents antigens and proteins
across membranes to strengthen immune response, which is mainly regulated by HSF1[188]. Taken together, it is highly possible that HSF-1 might interplay with DAF-16 and
SIR-2.1 to activate HSPs function in RJ/eRJ mediated heat shock stress resistance. Futher
experiments are needed to test our hypothesis.
It is well known that heat shock response is implicated in a series of conditions
and diseases, such as neurodegenerative diseases, ischemic diseases, infection, and aging.
Under stress conditions, proteins can be unfolded, misfolded, and aggregated[189].
Similarly, in the aging cells, the accumulated stresses and physiological decline
associated with aging cause damages to cells by promoting protein aggregation to disrupt
proteostasis[190]. In order to protect cells from this negative effect, cells themselves are
equipped with an internal repair system, which could produce more HSPs to refold or
degrade the destructed proteins and thereby assist the cell recovery in response to stresses.
Overall, our studies revealed that RJ/eRJ supplementation protected C. elegans from heat
shock stress, and this protection role reflected that RJ/eRJ posssessed capacity to assist C.
elegans in the repair of protein damage.
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In consideration that most neurodegenerative disorders are caused by protein
misfolding, studying the molecular mechanism of heat shock stress could further help us
to develop the therapeutic treatment of neurodegenerative diseases. RJ/eRJ
supplementation provided us with more opportunities to further investigate the detailed
molecular mechanism of heat shock resistance and age-related disorders. Additional
studies are needed to further understand the relationship between stress resistance and
pro-longevity.
In summary, our results demonstrated that RJ/eRJ can protect C. elegans from a
variety of stressors, such as oxidative stress, UV irradiation and heat shock stress. At
least in part, these beneficial effects might act through modulating the interplays of DAF16, SIR-2.1, HCF-1, and 14-3-3. Moreover, our quantitative PCR results showed that
RJ/eRJ induced the overexpression of several stress resistant genes under normal
conditions, which indicated that RJ/eRJ’s stress resistance capacity might be dependent
on its hermetic effects. It is conceivable that RJ/eRJ functions as a mild stress inducer to
ameliorate stress and promote longevity.
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CHAPTER FIVE : THE EFFECT OF ROYAL JELLY ON ALZHEIMER’S
DISEASE
5.1 Introduction:

Aging is the greatest cause of neurodegenerative diseases, and a sizable aging
population is already a major challenge for the healthcare system in American society.
The statistical data estimated that more than 20% of the population will be over 65 years
old by 2030, and the healthcare cost will reach $1.1 trillion by 2050[136].
Alzheimer’s disease (AD) is the best known and the most studied neurological
disorder in the aging population. AD is characterized by impairment of thinking,
communication, and memory[127]. Two obvious phenotypes of AD patients are brain
atrophy and neuropathological lesions, which exacerbate over time to interfere with daily
activities. Numerous studies demonstrated that in all AD patients the depositions of
neurofibrillary tangles (NFT) and extracellular amyloid plaques might disintegrate the
neuron’s signaling transduction systems and thereby induce neural cell death as well as
cognitive impairment[135].
A growing body of studies has been published to elucidate the molecular
mechanism of AD. Although the detailed molecular mechanism underlying AD is still
unclear, AD is often considered as a “protein misfolding disease”, because it is caused by
Aβ peptide aggregation and accumulation outside or inside of the neuronal cells[191]. It
is well known that free radicals are generated by cell metabolism and stressors during cell
growth, which cause damaging effects to the integrity of the proteome, leading to protein
misfolding, aggregation, and amyloid formation. In order to combat this negative effect,
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cells are equipped with protective machinery comprising a series of heat shock proteins
(HSPs) that refold or degrade the misfolded and unfolded proteins and thus maintain a
functional proteostasis. Unfortunately, the persisting harsh stresses and aging conditions
overwhelm this protective mechanism, leading to aberrant proteins aggregation and
cellular toxicity. It has been proposed that the aggregation and accumulation of these
aberrant proteins are common features of many neurodegenerative diseases[131].
AD, one of the costliest chronic diseases to society, has no efficient treatment;
thus there is an urgent need for scientists to investigate the pathologic mechanism of AD
and explore efficient therapeutic treatments to delay the progress of age-related disorders.
Because nearly 80% of genes and pathways related to human diseases are present and
conserved in C. elegans, it is believed that C. elegans is a good model to study the human
diseases and evaluate the efficiency of novel drugs and treatments. Specifically, the C.
elegans CL-2006 worm strain is reported as a classic AD model in many publications.
CL-2006 worms transgenically express human Aβ3-42 peptides in body wall muscle and
neuron cells. During the aging process, the aggregation and accumulation of Aβ species
in muscle cells result in a progressive or rapid paralysis phenotype, which can be used as
a direct indicator of Aβ toxicity[192].
To date, numerous findings have shown that C. elegans AD model provided an
excellent platform to investigate the beneficial anti-AD effects of nutraceuticals as well
as molecular mechanisms of AD[22]. For instance, recent studies using the C. elegans
model showed that curcumin, a phenol extracted from turmeric, could slow down the
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development of Alzheimer’s disease and Parkinson disease by alleviating the
proteotoxicity[193]. Guo et al reported that cranberry could protect worms against Aβ
toxicity in AD; IIS/HSF-1 was required in this beneficial effect[123]. Moreover, LWDH
(Liu Wei Di Huang), a traditional Chinese medicine, was discovered to delay AD
development by increasing the level of heat shock proteins (HSPs) in C. elegans AD
model[194]. Collectively, these studies show that dietary intervention provides a feasible
and efficient method to combat age-related disorders through the IIS pathway.
Our research focused on investigating the anti-aging effects of Royal Jelly. As a
functional nutraceutical product, Royal Jelly (RJ) and its derived products have
antimicrobial, anti-inflammation, immune-modulation, and anti-oxidation effects. The RJ,
a bee product, is secreted by worker bees and used for developing and maintaining the
queen bees. Enzyme treated RJ (eRJ) is produced by digestion of RJ with a hydrolytic
enzyme to decrease the allergenic properties of RJ[103]. In chapter four, our studies
demonstrated that RJ/eRJ extended C. elegans lifespan and protected them against
several stressors. Additionally, our genetic analysis showed that these beneficial effects
required IIS pathway and DAF-16, which has been reported to play a key role in
attenuating Aβ toxicity in C. elegans. To this end, it is highly possible that RJ/eRJ might
have a protective effect to slow down the development of AD in C. elegans model.
Herein, AD model CL-2006 worms were supplemented with RJ/eRJ to test this
hypothesis. Strikingly, our results showed that RJ/eRJ significantly slowed down the
progression of Aβ toxicity induced paralysis by reducing the Aβ species. Afterwards, the
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genetic analysis showed that this beneficial effect was dependent on IIS/DAF-16, rather
than HSF-1 and SKN-1. Our results consistently demonstrated that RJ/eRJ increased the
protein solubility to maintain a healthy proteostasis in aged worms. Given that AD is a
protein misfolding disease and caused by proteotoxicity, our western blot results showed
that RJ/eRJ could alleviate the cytotoxicity in AD worms by increasing the solubility of
Aβ species, which indicated that RJ/eRJ might influence the conformation of Aβ species
and thus slow down the development of AD.
Taken together, our findings not only implied the molecular mechanism of RJ/eRJ
mediated protection against Aβ toxicity but also shed light on the relationship between
proteostasis and neurodegenerative disorders.
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5.2 Results:
5.2.1 RJ/eRJ supplementation prolongs the lifespan of AD model C. elegans

It has previously been showed that RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ,
respectively) significantly increased the lifespan of wild type C. elegans, herein we want
to test whether RJ/eRJ also has the same beneficial effect on trans-genetic AD worms.
CL-2006 strain, engineered transgenic worms which express human Aβ proteins in body
muscles and neurons, were treated with our without RJ/eRJ from young adult stage, and
their lifespan were measured at 20°C. In consistent with our previous study, our data
showed that RJ/eRJ significantly increased the lifespan of CL-2006 worms. Comparing
with non-supplemented control, the mean lifespan of RJ/eRJ treated CL-2006 worms
averagely increased from 14.780 days to 17.000 days (RJ) and 17.188days (eRJ),
resulting in an increase of 15.02% and 16.29%, respectively (Figure 5.1 and Table 6).
Because of numerous studies revealed that lifespan extension is often associated with
increased stress resistance and anti-age related disorders function, this finding implied
that RJ/eRJ supplementation might be effective to AD treatment.
5.2.2 RJ/eRJ delays the progression of paralysis in AD worms by reducing the
amount of Aβ species

Paralysis is a major marker to directly reflect Aβ toxicity in AD worms. Briefly,
we investigated whether RJ/eRJ could slow down the progression of AD worms’
paralysis. Meanwhile, the amount of Aβ species was tested to determine whether RJ/eRJ
could influence Aβ production to affect Aβ-induced paralysis in AD worms.
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5.2.2.1 RJ/eRJ supplementation delays the progression of Aβ toxicity induced
paralysis in AD worms

Synchronized CL-2006 young adult worms were treated with or without RJ/eRJ
(2mg/mL RJ and 1mg/mL eRJ respectively) supplementation at 20°C and paralysis were
measured every day until all worms were paralyzed. Our data indicated that RJ/eRJ
supplementation dramatically delayed the progression of CL-2006 worms’ paralysis
when compared with the non-supplemented controls (Figure 5.2). Specifically, RJ/eRJ
extended the mean time of paralysis from 10.901 days to 12.656 days and 12.091 days,
displaying an average increase of mean paralysis time by16.10% and 10.92% when
compared with control group, respectively (Table 7). In considering that paralysis is a
direct indicator of Aβ toxicity, our finding suggested that in addition to lifespan extension,
RJ/eRJ also alleviated Aβ toxicity in AD model worms.
5.2.2.2 RJ/eRJ supplementation reduces Aβ species amount in AD worms

Given that AD worms’ paralysis is caused by Aβ toxicity, numerous studies
reported that many nutraceuticals possessed the ability to slow down the AD
development by mitigating Aβ toxicity through decreasing Aβ species. We questioned
whether RJ/eRJ followed the same rule to delay the development of AD. In order to
address this concern, synchronized CL-2006 young adult worms were treated with or
without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) for 10 days at 20°C.
Afterwards, 10-day aged worms were collected to conduct a dot blot assay to test whether
RJ/eRJ supplementation influenced the amount of Aβ species. Image-J software was used
to analyze the data. Our dot blot assay result showed that RJ/eRJ displayed a decrease of
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Aβ species amount by 13.61% and 21.90% comparing with non-supplemented controls,
which was statistically significant (p<0.05) (Figure 5.2). Taken together, given the
progression of CL-2006 worms’ paralysis is driven by Aβ toxicity and the amount of Aβ
species contributes to Aβ toxicity, out finding demonstrated that RJ/eRJ attenuated Aβ
toxicity by reducing the level of Aβ species amount.
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Figure 5.1 RJ and eRJ extend the lifespan of transgenic C. elegans expression
Aβ peptides. (A). Wild type N2 worms were supplemented with RJ/eRJ (2mg/mL RJ
and 1mg/mL eRJ, respectively). (B). CL-2006 worms, transgenic C. elegans
constitutively expressing Aβ, were treated with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ,
respectively). Each lifespan experiment was repeated at least three independent times
with similar results. Quantitative data and statistical analyses for the representative
experiments were included in Table 6.
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Figure 5.2 RJ/eRJ treatment mitigates Aβ toxicity in C. elegans by reducing Aβ
species amount. (A). CL-2006 worms were treated with RJ/eRJ (2mg/mL RJ and
1mg/mL eRJ, respectively) to carry out paralysis assays. The RJ/eRJ treated CL2006 worms (dashed line) showed delayed progression of body paralysis as
compared to control worms (solid line). Each paralysis assay was conducted in
triplicates and repeated at least three times with similar results. “% paralysis”
indicated the average paralysis among the multi-replicates and error bars represent
the standard deviation. (B). Dot blot analysis was carried out to measure the total
amount of Aβ species using 10-day old CL-2006 worms. Total Aβ species were
quantified by Image-J software. A dramatic reduction of total Aβ species were
observed in RJ/eRJ treated CL-2006 worms. The graph showed the mean intensity
of Aβ species and was the result of three independent experiments. The p value was
calculated by using Student’s t-test. “*” indicated p<0.05 when comparing to
controls.
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Table 6. The lifespan Data of N2 and CL-2006 worms at 20°C
strain
N2*
N2 + 2mg/mL RJ*
N2 + 1mg/mL eRJ*
CL-2006 **
CL-2006 + 2mg/mL RJ**
CL-2006 + 1mg/mL
eRJ**

Mean±SE
14.892±0.401
17.848±0.401
18.221±0.438
14.780±0.361
17.000±0.406

Median
15.00
18.00
19.00
15.00
18.00

No. of Worms
84
86
88
97
97

p value

17.188±0.312

17.00

105

0.001

0.002
0.001
0.001

Note: Lifespan and standard error are shown in days. The lifespan experiments were
repeated at least three times with similar results, and the data for representative
experiments are shown. The lifespan data were analyzed using the log-rank test and p
values for each individual experiment are shown.
*Results presented in Figure 5.1 A

**Results presented in Figure 5.1 B

Table 7. The Paralysis Data of CL-2006 Worms at 20°C
strain
†

CL-2006

CL-2006 + 2mg/mL RJ

†

CL-2006 + 1mg/mL eRJ

†

Mean±SE

Median

No. of Worms

p value

10.901±0.143

11.00

394

12.656±0.149

12.00

449

0.001

12.091±0.196

13.00

389

0.001

Notes: Paralysis and standard error were shown in days. The paralysis experiments were
repeated at least three times with similar results, and the data for representative
experiments were shown. The paralysis data were analyzed using the log-rank test and p
values for each individual experiment are shown.
†Results presented in Figure 5.2 A.

106

5.2.3 RJ/eRJ requires IIS/DAF-16, rather than HSF-1, SKN-1, and JNK-1, to delay
the development of body paralysis in C. elegans

Moll demonstrated that reduction of IIS prevented neurodegenerative diseases in
mammals and worms by increasing the transactivities of its transcriptional factors: DAF16, HSF-1, and SKN-1[143]. Moreover, it has been proposed that, in parallel to IIS, JNK
pathway also plays an important role in Alzheimer’s disease and regulate the activities of
these IIS pathway downstream transcriptional factors (DAF-16, SKN-1, and HSF-1).
Thus we wondered whether RJ/eRJ requires IIS pathway and JNK pathway to slow down
the development of AD in C. elegans.
5.2.3.1 Insulin Signaling Pathway and DAF-16 are required in RJ/eRJ mediated
protection from Aβ toxicity

In chapter three, our genetic analysis showed that IIS/DAF-16 was involved in
RJ/eRJ mediated lifespan extension. Considering the potential link between pro-longevity
and anti-AD function, we questioned whether IIS/DAF-16 also plays a key role in RJ/eRJ
mediated protection against Aβ toxicity. In order to address this concern, genetic epistasis
assays were carried out in CL-2006 worms treated with and without RJ/eRJ
supplementation to monitor their progression of paralysis.
Briefly, RNA interference (RNAi) was utilized to distinctively knock down the
gene expression of major IIS pathway components (daf-2 and age-1 respectively) and an
important IIS pathway downstream transcriptional factor (daf-16). CL-2006 worms were
synchronized on NGM plates seeded with particular RNAi or a paired RNAi control
(L4440 empty vector for age-1 RNAi and daf-16 RNAi, PAD-12 empty vector for daf-2

107

RNAi) bacteria. Afterwards, the synchronized young adult worms treated with or without
RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) were fed with particular RNAi
bacteria to carry out paralysis assays. Worms’ paralysis was observed every day until all
worms were paralyzed. Meanwhile, another set of young adult worms supplemented with
or without RJ/eRJ were fed with particular RNAi (daf-16, age-1, and daf-2, respectively)
and paired RNAi control bacteria for 6 days. Then the 6-day aged worms of different
treatments were collected to conduct a quantitative PCR experiment to check the RNAi
efficiency.
In our paralysis assay results, CL2006 worms fed with two RNAi paired control
bacteria were set up as system controls. When compare with non-treated controls, RJ/eRJ
supplementation dramatically delayed the progression of paralysis in CL-2006 worms fed
with two RNAi paired control bacteria, which confirmed that our experimental system
and RJ/eRJ treatment method worked well. Then we analyzed the paralysis assay data in
each RNAi (dat-16, age-1, and daf-2 respectively) bacteria fed worms. Interestingly, our
data showed that the beneficial effects of RJ/eRJ on delaying the progression of paralysis
was completely withdrew in CL-2006 worms fed with age-1 RNAi, daf-2 RNAi and daf16 RNAi bacteria comparing with RNAi matched non-supplemented controls,
respectively (Figure 5.3 A, B, and C). Moreover, the quantitative PCR results showed
that the RNAi successfully inhibited almost 80-90% gene expressions (age-1, daf-2, and
daf-16), respectively (Figure 5.3 D). This result indicated that RNAi method worked
efficiently to repress selected gene expression in genetic epistasis assays, and further
confirmed that our genetic epistasis assay results were reliable. Summarily, our findings
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showed that IIS and DAF-16 were required not only in RJ/eRJ mediated pro-longevity
effect but also in protection against Aβ toxicity.
In chapter three, we reported that RJ/eRJ extended C. elegans lifespan through
regulating the trans-activity of DAF-16. In consideration of DAF-16 was also involved in
RJ/eRJ mediated protection of Aβ toxicity, we questioned whether this beneficial effect
also acts through activating the DAF-16 target genes. To this end, synchronized CL-2006
young adult worms were treated with or without RJ/eRJ for 6 days, and several
representative DAF-16 target genes were selected to measure their expression levels in
each treatment. Our results showed that sod-3, mtl-1, Y71H2Ar.2, hsp-16.2, and hsp-12.6
were up-regulated in CL-2006 worms treated with RJ/eRJ when compared with nonsupplemented controls (Figure 5.4). This finding indicated that RJ/eRJ mediated
protection against Aβ toxicity might be dependent on elevating the transactivity of DAF16.
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Figure 5.3 RJ/eRJ requires IIS/DAF-16 to protect against Aβ toxicity in CL2006 worms. (A). RJ/eRJ cannot slow down the progression of body paralysis in CL2006 worms with reduced IIS by daf-2 RNAi. (B). RJ/eRJ cannot delay the progression
of Aβ toxicity-induced paralysis in CL-2006 worms with reduced IIS by age-1 RNAi. (C).
RJ/eRJ cannot delay the progression of Aβ toxicity-induced paralysis in CL-2006 worms
with reduced DAF-16 level by daf-16 RNAi. Each paralysis assay was repeated at least
three independent times with similar results. “% paralysis” indicated the average
paralysis among the multi-replicates and error bars represent the standard deviation. (D).
RNA interference efficiently knocked down selected gene expression (age-1, daf-2, and
daf-16 respectively) in CL-2006 worms’ genetic epistasis assays. The expression levels
of age-1, daf-2, and daf-16 were measured with qRT-PCR in CL-2006 worms
supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively). CL-2006 worms
feeding with paired RNAi control (L4440 empty vector for age-1 and daf-16, PAD-12
empty vector for daf-2) severed as controls to check gene knock down efficiency. The
data from three independent experiments were pooled to calculate the mean mRNA level
normalized to the internal control act-1. The standard errors of the mean (SEM) were
shown. “*” indicated p<0.05 when compared to paired RNAi bacteria controls.
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Figure 5.4 The transcript levels of mtl-1, sod-3, Y71H2AR.2, hsp-12.6, and hsp16.2 are up-regulated through RJ/eRJ mediated elevation of DAF-16’s transactivity. The expression levels of aip-1, F10D7.5, mtl-1, sip-1, sod-3, Y71H2AR.2, hsp12.6, hsp-16.2, hsp-70, and T02G5.10 were measure with qRT-PCR in CL-2006 worms
supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively). The data from
three independent experiments were pooled to calculate the mean mRNA level
normalized to the internal control act-1. The standard errors of the mean (SEM) were
shown. “*” indicated p<0.05 when compared to non-treated controls.
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Table 8. The Paralysis Data of Worms at 20°C
strain

Mean±SE

Median

No. of Worms

10.708±0.188

11.00

253

13.008±0.234

13.00

261

5.68E-05

12.379±0.223

12.00

256

1.41E-04

15.391±0.201

15.00

335

15.463±0.201

15.00

348

0.222

15.438±0.214

15.00

331

0.095

8.821±0.113

9.00

340

9.053±0.115

9.00

318

0.53

8.909±0.128

9.00

339

0.47

EV(PAD12) RNAi*

12.734±0.181

13.00

323

EV(PAD12) RNAi+RJ*
EV(PAD12) RNAi+eRJ*
daf-2 RNAi*
daf-2 RNAi+RJ*
daf-2 RNAi+eRJ*

15.699±0.205
15.006±0.194
19.253±0.273
19.389±0.313
19.296±0.305

16.00
15.00
20.00
20.00
21.00

316
315
348
314
301

EV(L4440) RNAi†,ⱡ
EV(L4440) RNAi+RJ

†,ⱡ

EV(L4440) RNAi+eRJ

†,ⱡ

†

age-1 RNAi

age-1 RNAi+RJ

†

age-1 RNAi+eRJ
daf-16 RNAi

†

ⱡ

daf-16 RNAi+RJ

ⱡ

daf-16 RNAi+eRJ

ⱡ

p value

1.31E-04
5.81E-05
0.712
0.728

Notes: Paralysis and standard error are shown in days. The paralysis experiments were
repeated at least three times with similar results, and the data for representative
experiments were shown. The paralysis data were analyzed using the log-rank test and p
values for each individual experiment are shown.
†Results presented in Figure 5.3 A
*Results presented in Figure 5.3 B
ⱡ Results presented in Figure 5.3 C
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5.2.3.2 HSF-1 and SKN-1, two other important transcriptional factors in IIS
pathway are dispensable in RJ/eRJ mediated protection against Aβ toxicity

Besides of DAF-16, SKN-1 and HSF-1 are another two important transcriptional
factors at the downstream of IIS pathway, and also play a key role in regulating Aβ
aggregation to alleviate Aβ toxicity in C. elegans. To this end, we examined whether
SKN-1 and HSF-1 were required in this RJ/eRJ mediated beneficial effect. CL-2006
worms supplemented with or without RJ/eRJ were fed with RNAi bacteria of skn-1 and
hsf-1, respectively. CL-2006 worms fed with RNAi control (L4440 empty vector)
bacteria served as a system control. Meanwhile, another set of young adult worms treated
with or without RJ/eRJ were fed with particular RNAi (skn-1 and hsf-1 respectively) and
paired RNAi control bacteria for 6 days. Then the 6-day old worms in each treatment
were collected to carry out a quantitative PCR experiment to check the efficiency of each
RNAi.
Our results showed that RJ/eRJ still delayed the progression of paralysis in CL2006 worms fed with skn-1 and hsf-1 RNAi bacteria respectively, comparing with
matched non-supplemented controls (Figure 5.5 A and B). Based on the analysis, RJ/eRJ
treated worms displayed an average increase of the mean paralysis time by of 24.67% (RJ)
and 22.18% (eRJ) when fed with hsf-1 RNAi bacteria. Similarly, RJ/eRJ supplemented
worms showed an average increase of mean paralysis time by 17.74% (RJ) and 16.56%
(eRJ) when fed with skn-1 RNAi bacteria, which were spastically significant when
comparing with non-treated control group (Table 9). Considering that in paired RNAi
control bacteria group, RJ/eRJ supplementation delayed 21.48% (RJ) and 15.61% (eRJ)
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of mean paralysis time when compared with non-supplemented controls, which were
nearly the same in hsf-1 and skn-1 RNAi bacteria fed worms. This comparison indicated
that SKN-1 and HSF-1 might be not dispensable in RJ/eRJ mediated protection against
Aβ toxicity. Moreover, RNAi efficiency was needed to be checked before we further
confirmed the genetic data. Our quantitative PCR results showed that the RNA
interference applied in this experiment successfully repressed almost 50% of skn-1 gene
expression and 90% of hsf-1 gene expression, which indicated that RNAi method worked
successfully to knock down selected gene expression in genetic epistasis assays and our
genetic results were reliable. Taken together, our findings suggested that SKN-1 and
HSF-1 were not required in RJ/eRJ mediated protection against Aβ toxicity.
5.2.3.3 JNK pathway is not required in RJ/eRJ mediated protection against Aβ
toxicity in AD worms

Our previous results showed that RJ/eRJ required IIS/DAF-16 to delay the
progression of paralysis in AD worms. It is well known that in addition to IIS pathway,
JNK pathway could also regulate the activity of DAF-16. Moreover, JNK pathway also
plays a key role in the development of neurodegenerative diseases. Next, we tested
whether jnk-1, a major component of JNK pathway, is required by RJ/eRJ in the
protection of Aβ toxicity. Following the same method, CL-2006 worms treated with or
without RJ/eRJ (2mg/mL RJ and 1mg/mL eRJ, respectively) were fed with jnk-1 RNAi
and control RNAi (L4440 empty vector) bacteria to observe paralysis. Meanwhile,
another set of worms treated with or without RJ/eRJ were fed with jnk-1 RNAi and
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control RNAi for 6 days. Then the 6 day old worms in each treatment were collected to
conduct a quantitative PCR experiment to check the efficiency of RNA interference.
Our results showed that RJ/eRJ still slowed down the progression of paralysis of
CL-2006 worms fed with jnk-1 RNAi bacteria (Figure 5.5 C). Specifically, RJ/eRJ
increased the mean paralysis time by 22.43% (RJ) and 22.59% (eRJ) when compared
with non-treated controls, and this increased rate was almost as same as RNAi control
bacteria (Table 9). Moreover, the quantitative PCR result showed that jnk-1 RNAi
applied in this experiment repressed almost 70% of jnk-1 gene expression, which
confirmed that jnk-1 RNAi efficiently knocked down jnk-1 gene expression in genetic
epistasis assays and our genetic results were reliable (Figure 5.5 D). Taken together, the
results suggested that JNK pathway were not required in RJ/eRJ mediated protection
against Aβ toxicity.
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Figure 5.5 RJ/eRJ mediated protection against Aβ toxicity is dispensable on
HSF-1, SKN-1 and JNK-1. (A). RJ/eRJ slowed down the progression of body
paralysis in CL-2006 worms with reduced HSF-1 level by hsf-1 RNAi. (B). RJ/eRJ
delayed the progression of toxicity-induced paralysis in CL-2006 worms with decreased
SKN-1 level by skn-1 RNAi. Each paralysis assay was repeated at least three independent
times with similar results. “% paralysis” indicated the average paralysis among the multireplicates and error bars represent the standard deviation. (C). RJ/eRJ mediated
protection against Aβ toxicity was dispensable on JNK pathway. RJ/eRJ slowed down the
progression of body paralysis in CL-2006 worms with reduced JNK-1 level by jnk-1
RNAi. Each paralysis assay was repeated at least three independent times with similar
results. “% paralysis” indicated the average paralysis among the multi-replicates and
error bars represent the standard deviation. (D). RNA interference efficiently knocked
down the selected gene expression (hsf-1, skn-1, and jnk-1, respectively) in CL-2006
worms’ genetic epistasis assays. The expression levels of hsf-1, skn-1, and jnk-1 were
measured with qRT-PCR in CL-2006 worms supplemented with RJ/eRJ (2mg/mL RJ and
1mg/mL eRJ, respectively). CL-2006 worms feeding with paired RNAi control (L4440
empty vector) severed as controls to check gene knock down efficiency. The data from
three independent experiments were pooled to calculate the mean mRNA level
normalized to the internal control act-1. The standard errors of the mean (SEM) are
shown. “*” indicated p<0.05 when compared to paired RNAi bacteria controls.
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Table 9. The Paralysis Data of CL-2006 Worms at 20°C
strain
EV(L4440) RNAi*,†,ⱡ
EV(L4440) RNAi+RJ

*,†,ⱡ

EV(L4440) RNAi+eRJ
jnk-1 RNAi*
jnk-1 RNAi+RJ*
jnk-1 RNAi+eRJ*
hsf-1 RNAi†
hsf-1 RNAi+RJ

†

hsf-1 RNAi+eRJ
skn-1 RNAi

†

ⱡ

skn-1 RNAi+RJ

ⱡ

skn-1 RNAi+eRJⱡ

*,†,ⱡ

Mean±SE

Median

No. of Worms

p value

10.708±0.188

11.00

253

13.008±0.234

13.00

261

5.68E-05

12.379±0.223
8.737±0.159
10.697±0.151
10.771±0.147

12.00
9.00
11.00
11.00

256
308
304
328

1.41E-04

9.401±0.187

10.00

309

11.720±0.166

12.00

307

2.65E-05

11.486±0.157

12.00

313

2.65E-05

10.435±0.167

11.00

294

12.286±0.197

13.00

311

0.001

12.163±0.183

13.00

301

0.001

1.37E-04
6.27E-05

Notes: Paralysis and standard error are shown in days. The paralysis experiments were
repeated at least three times with similar results, and the data for representative
experiments were shown. The paralysis data were analyzed using the log-rank test and p
values for each individual experiment are shown.
*Results presented in Figure 5.5 C
†Results presented in Figure 5.5 A
ⱡResults presented in Figure 5.5 B
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5.2.3.4 RJ/eRJ partially requires SIR-2.1, rather than HCF-1 and 14-3-3, to protect
AD worms against Aβ toxicity

In chapter three, we reported that SIR-2.1, HCF-1, and 14-3-3, three important
DAF-16 co-factors, modulated DAF-16 activity to extend the lifespan of C. elegans.
Considering that the link between pro-longevity and anti-AD functions, herein we
wondered whether these three proteins were involved in RJ/eRJ mediated protection of
Aβ toxicity. CL-2006 worms supplemented with or without RJ/eRJ were fed with RNAi
control (L4440 empty vector) bacteria and particular RNAi bacteria of sir-2.1, hcf-1, and
ftt-2, respectively. Meanwhile, another set of young adult worms treated with or without
RJ/eRJ were fed with particular RNAi (sir-2.1, hcf-1, and ftt-2, respectively) and paired
RNAi control bacteria for 6 days. Then the worms were collected to conduct a
quantitative PCR experiment to determine the efficiency of RNAi. Based on the analysis,
our results showed that RJ/eRJ still delayed the progression of paralysis in CL-2006
worms fed with sir-2.1, hcf-1, and ftt-2 RNAi bacteria respectively, when compared with
matched non-supplemented controls (Figure 5.6 A, B, and C). It is worth noticing that
RJ/eRJ supplemented worms displayed an increase of mean paralysis time by 7.07% (RJ)
and 7.03% (eRJ) when fed with sir-2.1 RNAi bacteria comparing with the non-treated
controls fed with the same RNAi bacteria. However, in the paired RNAi control bacteria
group, RJ/eRJ supplementation extended 21.48% (RJ) and 15.61% (eRJ) of mean
paralysis time when compared with non-supplemented controls, which were nearly 2 to 3
times longer than the increased rates in sir-2.1 RNAi bacteria group (Table 10). These
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results demonstrated that SIR-2.1 was partially required in RJ/eRJ mediated protection of
Aβ toxicity.
Next, the same strategy was utilized to analyze whether another two proteins,
HCF-1 and 14-3-3, are involved in this RJ/eRJ mediated beneficial effect. Specifically,
RJ/eRJ supplemented CL-2006 worms showed an average increase of mean paralysis
time by 20.19% (RJ) and 14.84% (eRJ) when fed with ftt-2 RNAi bacteria. Similarly,
RJ/eRJ supplemented worms showed an average increase of mean paralysis time by
13.31% (RJ) and 12.98% (eRJ) when fed with hcf-1 RNAi bacteria. Interestingly, unlike
sir-2.1 RNAi treatment, these two genes RNAi paralysis assays showed the RJ/eRJ
mediated mean paralysis extended rates were almost the same in worms fed with hcf-1
RNAi and ftt-2 RNAi bacteria groups, when compared with worms fed with paired RNAi
control bacteria (Figure 5.6 B and C). These data implied that HCF-1 and 14-3-3 were
dispensable in RJ/eRJ mediated protection of Aβ toxicity.
In order to confirm our genetic data, a quantitative PCR experiment result was
carried out to check the efficiency of RNAi. As we had expected, the RNAi applied in
this experiment repressed almost 80% of sir-2.1 gene expression, 75% of ftt-2 gene
expression, and 85% of hcf-1 gene expression (Figure 5.6 D). These results indicated that
RNAi successfully knocked down the selected genes expression in paralysis assays and
further confirmed that our genetic analysis data were reliable. Collectively, our results
suggested that SIR-2.1 was partially required in RJ/eRJ mediated protection against Aβ
toxicity, whereas HCF-1 and 14-3-3 were dispensable in this beneficial effect.
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Figure 5.6 RJ/eRJ mediated protection against Aβ toxicity is dispensable on
HCF-1 and 14-3-3, but partially dependent on SIR-2.1. (A). RJ/eRJ slowed down
the progression of body paralysis in CL-2006 worms with reduced SIR-2.1 level by sir2.1 RNAi. (B). RJ/eRJ delayed the progression of toxicity-induced paralysis in CL-2006
worms with decreased HCF-1 level by hcf-1 RNAi. (C). RJ/eRJ delayed the progression
of toxicity-induced paralysis in CL-2006 worms with decreased 14-3-3 level by ftt-2
RNAi. Each paralysis assay was repeated at least three independent times with similar
results. “% paralysis” indicated the average paralysis among the multi-replicates and
error bars represent the standard deviation. (D).RNA interference efficiently knocked
down selected gene expression (sir-2.1, hcf-1, and ftt-2, respectively) in CL-2006 worms’
genetic epistasis assays. The expression levels of sir-2.1, hcf-1, and ftt-2 were measured
with qRT-PCR in CL-2006 worms supplemented with RJ/eRJ (2mg/mL RJ and 1mg/mL
eRJ, respectively). CL-2006 worms feeding with paired RNAi control (L4440 empty
vector) severed as controls to check gene knock down efficiency. The data from three
independent experiments were pooled to calculate the mean RNA level normalized to the
internal control act-1. The standard errors of the mean (SEM) were shown. “*” indicated
p<0.05 when compared to paired RNAi bacteria controls.
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Table 10. The Paralysis Data of CL-2006 Worms at 20°C
strain
EV(L4440) RNAi*
EV(L4440) RNAi+RJ*
EV(L4440) RNAi+eRJ*
sir-2.1 RNAi*
sir-2.1 RNAi+RJ*
sir-2.1 RNAi+eRJ*

Mean±SE
10.708±0.188
13.008±0.234
12.379±0.223
10.520±0.151
11.264±0.172
11.260±0.166

Median
11.00
13.00
12.00
11.00
12.00
12.00

No. of Worms
253
261
256
277
277
285

EV(L4440) RNAi†,ⱡ

11.099±0.133

11.00

332

12.848±0.179

13.00

329

7.51E-04

12.477±0.163

13.00

329

8.68E-04

10.381±0.147

10.00

381

12.477±0.186

12.00

329

3.13E-04

11.922±0.160

12.00

375

4.28E-04

13.005±0.121

13.00

381

14.736±0.146

15.00

329

0.002

14.693±0.133

15.00

375

0.002

EV(L4440) RNAi+RJ

†,ⱡ

EV(L4440) RNAi+eRJ
†

ftt-2 RNAi

ftt-2 RNAi+RJ†
ftt-2 RNAi+eRJ
hcf-1RNAi

†

ⱡ

hcf-1 RNAi+RJ

ⱡ

hcf-1 RNAi+eRJ

ⱡ

†,ⱡ

p value
5.68E-05
1.41E-04
0.002
0.002

Notes: Paralysis and standard error were shown in days. The paralysis experiments were
repeated at least three times with similar results, and the data for representative
experiments are shown. The paralysis data were analyzed using the log-rank test and p
values for each individual experiment are shown.
*Results presented in Figure 5.6 A
†Results presented in Figure 5.6 B
ⱡResults presented in Figure 5.6 C
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5.2.4 RJ/eRJ supplementation increases protein solubility in aged C. elegans

Aging and persisting stresses cause cumulative damages to cells, which could
destruct proteins’ conformation to induce the deposition of insoluble proteins. Some
nutraceuticals could combat this damage by promoting the protein solubility to maintain a
functional proteostasis. Considering that RJ/eRJ slowed down the progression of
paralysis in AD worms, we wondered that whether RJ/eRJ’s beneficial effect is
dependent on promoting solubility of proteins in aged worms. To this end, synchronized
young adult N2 worms and CL-2006 worms were treated with or without RJ/eRJ for 10
days. Then the aged worms were collected for total proteins extraction. After sonication
and high speed centrifugation, soluble fraction was isolated from the total proteins. SDSPAGE and Image-J were utilized to investigate whether RJ/eRJ affect the solubility of
proteins in aged C. elegans. Our results showed that RJ/eRJ increased 26.95% (RJ) and
26.87% (eRJ) soluble protein amount relative to non-supplemented controls in N2 worms.
Similarly, RJ/eRJ also displayed an average increase of CL-2006 worms’ soluble proteins
amount by 27.13% (RJ) and 21.27% (eRJ) when compared with controls without RJ/eRJ
supplementation (Figure 5.7 A and B). These results were statically significant, which
indicated that RJ/eRJ improved functional proteostasis in aged C. elegans.
Our previous results indicated that DAF-16 was required in RJ/eRJ mediated
lifespan extension, stress resistance, and protection against Aβ toxicity. It is highly
possible that DAF-16 might also be required in increasing the protein solubility under
RJ/eRJ supplementation. In order to confirm this hypothesis, synchronized daf-16
(mgDf50) mutant worms and daf-16 RNAi bacteria feeding CL-2006 worms were treated
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with or without RJ/eRJ for 10 days. Then the aged worms were collected for total protein
extraction. Sonication and centrifugation were utilized to remove the insoluble proteins,
and the amount of soluble protein was measure by SDS-PAGE and Image-J software.
Specifically, RJ/eRJ still increased the amount of soluble proteins by 5.44% (RJ) and
2.20% (eRJ) when compared with the non-treated controls in daf-16 deletion mutant
worms. Additionally, RJ/eRJ increased the amount of soluble proteins by 5.12% (RJ) and
3.82% (eRJ) when compared with the non-supplemented controls in CL-2006 worms fed
with daf-16 RNAi bacteria (Figure 5.8 A and B). However, the student t test showed that
these increases were not statistically significant. To this end, these results indicated that
RJ/eRJ cannot improve protein solubility of daf-16 deletion mutant worms and daf-16
knocked down CL-2006 worms.
Taken together, RJ/eRJ improved protein solubility in aged worms and thus
delayed the development of AD. Noticeably, DAF-16 displayed a very important role in
this process to maintain a healthy proteostasis.
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A

B

Figure 5.7 RJ/eRJ improves proteostasis in aged C. elegans. (A). RJ/eRJ
treatment increased protein solubility in 10-day old N2 worms. (B). RJ/eRJ
supplementation increased protein solubility in 10-day old CL-2006 worms. Soluble
proteins on the SDS-PAGE gel were quantified by using Image-J software. Data were
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expressed as mean intensity from three independent experiments. The standard errors of
the mean (SEM) were shown. p value was calculated using Student’s t-test. “*” indicated
p <0.05 when compared to controls.

A

B
10-day old adult CL-2006
fed with daf-16 RNAi bacteria
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Figure 5.8 RJ/eRJ improves proteostasis in aged C. elegans dependent on DAF16. (A). RJ/eRJ treatment increased protein solubility in 10-day old daf-16 (mgDf50)
mutant worms. (B). RJ/eRJ supplementation increases protein solubility in 10-day old
CL-2006 worms fed with daf-16 RNAi bacteria. Soluble proteins on the SDS-PAGE gel
were quantified by using Image-J software. Data were expressed as mean intensity from
three independent experiments. The standard errors of the mean (SEM) were shown. p
value was calculated using Student’s t-test. “*” indicated p <0.05 when compared to
controls.
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5.2.5 RJ/eRJ supplementation significantly increases solubility of Aβ species in
aged worms

It is well known that healthy aging is often associated with functional proteostasis
to reduce the proteotoxicity in cells. Given that RJ/eRJ could mitigate Aβ toxicity in AD
worms, we wondered whether RJ/eRJ might promote the solubility of Aβ species in aged
worms. To address this question, synchronized young adult CL-2006 worms were
supplemented with or without RJ/eRJ for 10 days. Then the 10-day aged worms were
collected for total proteins extraction. Sonication and centrifugation were utilized to
divide proteins into soluble fraction and insoluble fraction. Afterwards, the amount of
soluble Aβ species and insoluble Aβ species were measures by western blot and Image-J
software. Our results showed that RJ/eRJ increased solubility of Aβ species in aged AD
worms. Specifically, comparing with non-treated controls, RJ/eRJ supplementation
increased the amount of soluble Aβ species 21.71% (RJ) and 19.31% (eRJ), whereas the
amount of insoluble Aβ species was decreased by 27.63% (RJ) and 28.61% (eRJ),
respectively (Figure 5.9 A and B). Considering that RJ/eRJ dramatically slowed down the
progression of paralysis in AD worms, this result indicated that RJ/eRJ might promote
the solubility of Aβ species in a toxicity reduction manner.
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10-day old adult
CL-2006

*
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Figure 5.9 RJ/eRJ improves solubility of Aβ species in aged CL-2006 worms.
(A). RJ/eRJ supplementation increased soluble Aβ species in 10-day old CL-2006 worms.
(B). RJ/eRJ supplementation decreased insoluble Aβ species in 10-day old CL-2006
worms. The amount of soluble and insoluble proteins was quantified by using western
blot and Image-J software. DATA were expressed as mean intensity from three
independent experiments. The standard errors of the mean (SEM) were shown. p value
was calculated using Student’s t-test. “*” indicated p <0.05 when compared to controls.

135

5.3 Discussion

In chapter three and four, our results showed that RJ/eRJ supplementation had
beneficial effects of pro-longevity and stress resistance in C. elegans. A growing body of
evidence suggests that some anti-aging nutraceuticals could delay the development of
neurodegenerative diseases[123, 146, 195]. For example, cranberry protected C. elegans
from thermal stress and slowed down the development of AD; Resveratrol, an antioxidant
component from grape seed, not only had pro-longevity function but also delayed the
development of Alzheimer’s diseases and Parkinson’s disease[147]. Therefore, it is
interesting to further investigate whether RJ/eRJ also has the capacity to slow down the
development of Alzheimer’s disease.
CL-2006 mutant stain, an AD C. elegans model, which transgenically expresses
human Aβ3-42 in the worms’ body muscle cells, has been considered as a well-established
model to investigate the link between AD and Aβ pathology[192]. During the aging
process, Aβ species were aggregated and accumulated inside and outside the muscle and
neuron cells, which causes the worms’ body paralysis via deposition of cytotoxic plaques.
To date, paralysis is a direct indicator to reflect Aβ toxicity in AD worms.
In our study, our results showed that RJ/eRJ supplementation reduced the total
amount of Aβ species and thereby delayed the progression of paralysis in AD worms.
Additionally, RJ/eRJ supplemented CL-2006 worms’ lifespan. It is worth noticing that RJ
treatment better protected AD worms from Aβ toxicity when compared with eRJ
treatment. Our paralysis assay results showed that RJ/eRJ treatment increased the mean
time of paralysis by 16.10% (RJ) and 10.92% (eRJ) when compared with the mean
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paralysis time in non-supplemented controls in CL-2006 worms feeding with OP50 E.
coli (figure 5.2 A and Table 7). Moreover, RJ/eRJ supplementation extended the mean
paralysis time by 21.48% (RJ) and 15.61% (eRJ) when compared with the mean paralysis
time in non-supplemented controls in CL-2006 worms feeding with RNAi control (L4440
empty vector) bacteria. In addition to these two sets of data, another RNAi control
(PAD12 empty vector) bacteria treatment also showed the same trend that RJ extended
nearly 1 day longer of mean paralysis when compared with the mean time of paralysis in
eRJ treatment. In agreement with these paralysis assay results, our dot blot assay showed
that RJ treatment reduced 21.49% Aβ species, while eRJ treatment only reduces 14.51%
Aβ species.
As we mentioned in chapter three, the difference between the two types of RJ
powders is that RJ contains more large proteins than eRJ powder. It is possible that these
large proteins might promote immune response to eliminate toxic Aβ species. In
agreement with these paralysis assay results, our dot blot assay showed that RT treatment
reduced the Aβ species by 21.49%, while eRJ treatment only reduced the Aβ species by
14.51%, comparing with the amount of Aβ species in non-supplemented controls.
However, further experiments are needed to be done to better elucidate the different
beneficial effects between RJ and eRJ powders.
In our study, CL-2006 worms were treated with RJ/eRJ after L4/young adult stage
rather than egg stage. The reason was that RJ/eRJ affected the hatching rate and
development of CL-2006 worms. This negative effect was only observed in CL-2006
strain rather than other types of worms in the previous study. Based on our observation,
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when CL-2006 worms were treated with RJ/eRJ from the egg stage, their hatching rate
and worms’ size were reduced when compared with that of non-treated CL-2006 worms.
To note, these negative effects were even worse in RJ treatment than eRJ treatment. It is
possible that RJ/eRJ might contain some proteins to reduce CL-2006 worms’ hatching
rate and affect their development to a certain degree. Moreover, the large proteins in RJ
powder might dramatically exacerbate these negative effects.
Generally, although there were some differences between RJ/eRJ’s protein
component and beneficial effects, both RJ and eRJ could slow down the progression of
Aβ toxicity induced paralysis. Considering that CL-2006 worms’ Aβ species were human
derived, it is highly possible that RJ/eRJ supplementation might have potential capacity
to mitigate Aβ toxicity in humans. However, clinical research is needed to further
confirm this hypothesis.
As shown in this chapter, RJ/eRJ supplementation possessed the ability to
alleviate Aβ toxicity in AD worms. However, the molecular mechanism underlying this
beneficial effect is unknown. Moll and colleagues reported that reduction of Insulin
Signaling (IIS) Pathway could prevent neurodegeneration in worms and mammals. They
demonstrated that the reduction of IIS pathway could activate its three important
transcriptional factors. DAF-16, HSF-1, and SKN-1, to inhibit age-mediated
proteotoxicity and thereby maintain a healthy aging[144]. It is possible that IIS pathway
and its three important transcriptional factors might also play a key role in RJ/eRJ
mediated protection against Aβ toxicity. To address this concern, RNA interference
(RNAi) was utilized to inhibit the gene expression of two important components (daf-2
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and age-1) and three transcriptional factors (daf-16, skn-1, and hsf-1), respectively, to
conduct genetic epistasis assays. Our findings indicated that IIS and DAF-16, rather than
HSF-1 and SKN-1 were required in this RJ/eRJ mediated beneficial anti-AD effect
(Figure 5.3 and 5.5). Moreover, quantitative PCR experiments were carried out to test
whether DAF-16’s trans-activity is influenced by RJ/eRJ supplementation. As expected,
the increased level of sod-3 and mtl-1 confirmed that RJ/eRJ supplementation elevated
the transactivity of DAF-16. Additionally, other DAF-16 target genes, Y71H2AR.2, hsp12.6, and hsp-16.2, were also up-regulated in RJ/eRJ treated CL-2006 worms (Figure 5.4).
Taken together, the genetic analysis and quantitative PCR results indicated that RJ/eRJ
alleviated Aβ toxicity via influencing IIS pathway to elevate the transactivity of DAF-16.
SKN-1 and HSF-1 are also important factors to protect organisms from
proteotoxicity by maintaining a healthy proteostasis. For example, HSF-1 regulates
numerous heat shock proteins (HSPs) to facilitate the refolding of misfolded proteins in
neurodegenerative diseases[37]. Similarly, SKN-1 also plays an important role in
controlling protein quality and regulating detoxification of proteome[40, 196]. It is well
known that a functional proteostasis could reduce the proteotoxicity and thereby alleviate
the progression of paralysis. However, our genetic results showed that RJ/eRJ
supplementation still dramatically extended the mean time of paralysis dramatically when
compared with non-treated controls in hsf-1 RNAi bacterial treatment and skn-1 RNAi
bacterial treatment (Figure 5.5) when compared the data among these two treatments and
paired RNAi control (L4440 empty vector) bacteria, the increasing rates of mean
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paralysis time were nearly the same (Table 9). This result further confirmed that SKN-1
and HSF-1 were dispensable in RJ/eRJ mediated protection against Aβ toxicity.
In addition to IIS pathway, the JNK pathway is also reported as an important
regulator in neurodegenerative disorders. Specifically, Chen’s lab demonstrated that JNK
pathway was significantly up-regulated in AD mammalian models[197]. Based on our
knowledge, JNK-1, an essential regulator in the JNK pathway, could modulate DAF-16,
HSF-1, and SKN-1 in parallel to IIS pathway. Intriguingly, our results showed that
RJ/eRJ treatment extended the same rates of mean paralysis in CL-2006 worms feeding
with jnk-1 RNAi bacteria and paired RNAi control (L4440 empty vector) bacteria (Figure
5.5 and Table 9). These results indicated that JNK pathway was not required in RJ/eRJ
mediated protection against Aβ toxicity.
In chapter three and four, our research revealed that besides DAF-16, co-factors
SIR-2.1, HCF-1, and 14-3-3 also play a very important role in RJ/eRJ mediated prolongevity and stress resistance. Based on these results, we questioned whether these three
DAF-16 co-factors are involved in RJ/eRJ mediated anti-AD function. Our results
showed that SIR-2.1, rather than HCF-1 and 14-3-3, were partially required in RJ/eRJ
mediated protection against Aβ toxicity. Unlike DAF-16, SIR-2.1 was partially involved
in RJ/eRJ mediated anti-AD effect, because our genetic data showed that RJ/eRJ still
extended the mean time of paralysis by by 7.07% (RJ) and 7.03% (eRJ) in CL-2006
worms feeding with sir-2.1 RNAi bacteria (Table 10), but this increasing rate was only
half of the increasing rate in worms fed with CL-2006 RNAi control bacteria.
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Numerous studies have revealed that SIRT1/SIR-2.1 plays a key role in
prevention of neurodegenerative diseases. Araki reported that SIRT1 repressed axonal
degeneration to decrease neuronal death rate in AD and Parkinson’s disease in murine
model[198]. Besides neuronal protection, Chen lab discovered that overexpression of
SIRT1 could inhibit NF-κB signaling via decreasing the acetylation of RelA/P65, which
in turn protected mice against Aβ toxicity in AD development[199]. In agreement with
their mammalian studies, our results showed that SIR-2.1 was partially involved in
RJ/eRJ mediated protection against Aβ toxicity. Given that SIR-2.1 is an important DAF16 co-factor to fine-tunes DAF-16’s transactivity in RJ/eRJ mediated pro-longevity and
stress resistance effects, it is conceivable that SIR-2.1 might modulate DAF-16’s
transactivity to slow down the progression of CL-2006 worms’ paralysis under RJ/eRJ
supplementation. Further experiment is needed to better understand the function of SIR2.1 in neurodegenerative diseases. Taken together, although three DAF-16 factors-SIR2.1, HCF-1, and 14-3-3-were involved in pro-longevity and stress resistance under
RJ/eRJ supplementation, only SIR-2.1 was further required in RJ/eRJ mediated
protection against Aβ toxicity in the AD worm model.
Considering that RJ/eRJ supplementation mediated anti-AD effect acted through
IIS pathway and DAF-16, we further questioned how IIS/DAF-16 functions in this
process. Several studies demonstrated that the imbalance of proteostasis is often linked to
neurodegenerative diseases. For instance, Ben-Zvi further demonstrated that an agerelated protein homeostasis disorders may lead to impaired protein solubility and
increased cytotoxicity[190]. Reis-Rodrigues and colleagues further claimed that
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accumulation of insoluble proteins with diverse biological functions may be shared as a
general feature of normal aging and late onset neurodegenerative diseases[200]. The
collective research of these age-related studies showed that better protein solubility
directly reflects the heathier proteostasis and lower proteotoxicity. Interestingly, our
results showed that RJ/eRJ significantly increased protein solubility in aged wild type
worms and AD worms, which indicated that RJ/eRJ treated worms acquired the capacity
to maintain a healthy proteostasis. Our previous results showed that DAF-16 was
required in RJ/eRJ mediated protection against Aβ toxicity, which implied that RJ/eRJ
might also require DAF-16 to retain a healthy proteostasis. In accordance with this
hypothesis, our further solubility assay showed that the protein solubility of aged daf-16
deletion mutant worms was barely influenced by RJ/eRJ supplementation. Taken together,
our results indicated that RJ/eRJ improved the healthy proteostasis to mitigate Aβ
toxicity in aged worms. This beneficial effect was dependent on DAF-16.
It is worth noticing that RJ/eRJ supplementation remarkably increased the
solubility of high molecular weight (HMW) proteins (protein size over 70 KD) by more
than 2 fold when compared with the increasing rates of solubility for low molecular
weight (LMW) proteins (protein size smaller than 70 KD) (Figure 5.10 A and B).
However, in daf-16 (mgDf50) and daf-16 RNAi feeding AD worms, this difference of
increasing ratios in HMW soluble proteins and LMW soluble proteins was abolished,
indicating that DAF-16 played a very important role in maintaining the configuration of
large soluble proteins (Figure 5.10 C and D). As of yet, there is no conclusive evidence
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proving the relationship between the well-maintained conformation of LMW and healthy
aging, but the further research would confirm this relationship.
To date, more and more research lab focus on investigating the link between Aβ
conformation and its toxicity. Several clinical studies revealed that the amount of Aβ
species detected in AD patients was not always higher than healthy people, which
indicated that the amount of Aβ species is not a direct indicator to determine AD[201].
Furthermore, numerous studies have shown that not all of Aβ species are toxic to induce
AD pathology, and the toxicity of Aβ species were dependent on their conformation[202].
Specifically, some scientists discovered that LMW Aβ/ Aβ oligomers which prone to
seed Aβ aggregation could accelerate the development of neurodegenerative diseases and
proteinopathy[203]. Although the detailed molecular mechanism of proteotoxicity
underlying neurodegenerative diseases is still unclear, numerous studies demonstrated
that IIS pathway and its three critical transcriptional factors play an important role to
regulate protein aggregation and proteotoxicity. In order to decipher the molecular
mechanism of Aβ induced cytotoxicity, Cohen research lab reported that DAF-16 can
promote protein aggregation to protect cells from the accumulation of soluble and toxic
protein species[204].
In our research, the solubility results implied that DAF-16 was regulated by
RJ/eRJ supplementation to increase more than 2 times of soluble HMW proteins than
LMW proteins in aged worms. There are two possible reasons to explain this
phenomenon. First, in agreement with Cohen’s discovery, DAF-16 could promote soluble
LMW proteins aggregation to form more soluble HMW proteins in aging process.
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Another possibility is that DAF-16 protected HMW proteins from degradation by
retaining their soluble status conformation and stability. Based on our results, it is hard to
tell whether DAF-16 functions to promote protein aggregation or prevent the degradation
of HMW proteins. Therefore, further research was needed to be carried out to investigate
DAF-16’s function in proteostasis. Taken together, our findings suggested that RJ/eRJ
supplementation improved the healthy proteostasis by maintaining the functional protein
conformation in aged worms.
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Figure 5.10 RJ/eRJ supplementation remarkably increases the solubility of
high molecular weight (HMW) proteins (protein size over 70 KD) more than
low molecular weight (LMW) proteins in a DAF-16 dependent manner. (A).
RJ/eRJ treatment increased more HMW protein solubility than LMW protein solubility in
10-day old N2 worms. (B). RJ/eRJ treatment increased more HMW protein solubility
than LMW protein solubility in 10-day old CL-2006 worms. (C). RJ/eRJ treatment
increased same ratio of HMW protein solubility and LMW protein solubility in 10-day
old daf-16 (mgDf50) worms. (D). RJ/eRJ treatment increases same ratio of HMW protein
solubility and LMW protein solubility in 10-day old CL-2006 worms feeding with daf-16
RNAi bateria. Soluble proteins on the SDS-PAGE gel are quantified by using Image-J
software. Data were expressed as mean intensity from three independent experiments.
The standard errors of the mean (SEM) were shown. p value was calculated using
Student’s t-test. “*” indicated p <0.05 when compared to controls.
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It is well known that a healthy proteostasis indicates a balance of protein synthesis,
folding, aggregation, and degradation. However, imbalance among these processes
engenders deposition and aggregation of aberrant proteins, causing toxicity and damge to
induce age-related disorders. In order to fight against this negative impact, cells are
equipped with protective machinery to maintain a protein homeostasis in normal
condition. The misfolded and unfolded proteins are usually refolded by HSPs or targeted
by ubiquitin for proteasomal or lysosomal degradation[205]. However, this mechanism is
overwhelmed in aging cells or under persisting harsh stresses conditions. As a result, the
misfolded and unfolded proteins are aggregated and accumulated inside and outside the
cells instead of being refolded or destroyed, and thus induces the neurodegenerative
disorders. It is well known that HSPs function as a master regulator to maintain this
important machinery in all conditions[187]. Several studies demonstrated that even
overexpression of one HSP could dramatically delay the neurodegenerative diseases,
which underscored HSPs’ critical function in retaining the healthy proteostasis.
In agreement with this view, RJ/eRJ supplementation also positively regulated
the levels of several protein turnover genes in AD worms, such as mtl-1, hsp-12.6, hsp16.2, and Y71H2AR.2. mtl-1, an important downstream genes of DAF-16, plays an
important role in metal detoxification and maintaining the protein homeostasis in stress
conditions[206]. HSP-12.6 and HSP-16.2 are two essential heat shock proteins, which
function as ubiquitous molecular chaperones to prevent the aggregation of misfolded and
unfolded proteins in response to proteotoxic stressors[196, 207]. Additionally, Link’s lab
discovered that overexpression of HSP-16.2 could suppress the Aβ toxicity in AD worms,
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which might be selected as a target to design anti-AD drugs. The last gene dramatically
influenced by RJ/eRJ treatment was Y71H2AR.2, which encodes a papain family cysteine
protease to modulate proteolysis[208]. The up-regulated of this gene might indicate a
well-maintained detoxification function to destruct the aberrant proteins. Besides protein
folding and degradation, we also investigate whether RJ/eRJ supplementation could
affect CL-2006 worms’ protein synthesis. Intriguingly, ZK218.8 and T05G5.10, which
encode translation initiation factor 2C and 5A respectively, were not affected by RJ/eRJ
supplementation in our quantitative PCR experiment[209]. Collectively, the elevated
expression level of these DAF-16 targeted protein turnover genes indicated that RJ/eRJ
improve the healthy proteostatic status by strengthening the function of protein folding
and degradation in AD worms.
Besides these genes, several protein turnover related genes’ level were also
measured in our quantitative PCR experiment. sip-1 (stress induced protein 1) and hsp70
are also reported to control protein quality, guide protein folding, and maintain proteins’
biological function[118, 210]. aip-1 (arsenite inducible protein) and F10D7.5 are
important regulator to induce the degradation of toxic proteins under stress or disease
conditions[209, 211]. To note, it is reported that aip-1 played an important role to
regulate 26S proteasome in response to protein aggregation in AD. In contrast, no study
demonstrated F10D7.5’s function in AD related research, but this gene encodes one of
the E3 ubiquitin ligases in C. elegans, which could bind the target protein and E2 enzyme
together to signal ubiquitin targeted protein degradation or modulate its function.
Unfortunately, these genes were not affected by RJ/eRJ supplementation in AD worms. It
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is well known that AIP-1, SIP-1, and HSP-70 were mainly regulated by HSF-1, and HSF1 was not required in RJ/eRJ mediated protection against Aβ toxicity. Thus this result
further confirmed our genetic data and supported our proposed genetic model.
Additionally, this result indicated that DAF-16’s activity is fine-tuned by co-factors and
pathways. Further experiments are needed to best understand the precise posttranslational modification of DAF-16 under RJ/eRJ supplementation, which will provide
novel ideas to develop effective anti-AD drugs.
Given that RJ/eRJ supplementation could promote the functional proteostasis to
attenuate proteotoxicity in aging cells, next we tested whether RJ/eRJ mediated Aβ
detoxification acted through affecting the solubility of Aβ species. Our results showed
that RJ/eRJ supplemented worms’ soluble Aβ species were significantly higher than nontreated CL-2006 worms, while the insoluble Aβ species in RJ/eRJ treated worms were
dramatically lower when compared with non-treated controls (Figure 5.9 A and B). In
consideration of RJ/eRJ possessed the ability to alleviate Aβ toxicity in AD worms, our
finding suggested that RJ/eRJ mediated Aβ species detoxification might act through
changing the conformation of Aβ proteins to alleviate its toxicity in AD worms.
Tyedmers and colleagues reported that the forming aggregates’ structure varied from
most disordered aggregates to prefibrillar species and highly ordered amyloid fibrils in
AD patients’ cells. Comparing with highly ordered aggregates, the unstructured and
disordered aggregates are dramatically inclined to be degraded and thereby be considered
as less toxic aggregates. Noticeably, chaperones play an important role in this aggregates
formation process[131, 212]. Given that RJ/eRJ changed the solubility of Aβ species in
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aged worms and up-regulated the levels of several chaperone proteins, it is possible that
RJ/eRJ could promote the formation of disordered Aβ aggregates instead of highly
ordered insoluble Aβ aggregates and hence improves the detoxification of Aβ species in
AD worms.
Further experiment is needed to be carried out to best understand how Aβ
conformation is changed and detoxified by DAF-16. Numerous studies revealed that the
Aβ3(PE)-42 was one type of toxic Aβ species, which formed more than 50% of Aβ plaques
in cells and seeded Aβ aggregation to accelerate the development of AD. Accordingly,
glutaminyl cyclase (QC) has been proposed to catalyze Aβ3-42 to Aβ3(PE)-42 in clinical
study to exacerbate neuronal cytotoxicity. It is possible that RJ/eRJ might possess
capacity to affect Aβ species conformation by influencing QC[213]. Currently, there is no
publication talking about the link between Aβ conformation and QC in C. elegans model,
and further research will investigate this relationship.
Overall, our finding not only demonstrated that the molecular mechanisms of
RJ/eRJ mediated alleviation of Aβ toxicity in C. elegans but also underscored RJ/eRJ’s
potential function to lead a healthy aging. In considering that IIS/DAF-16 is highly
conserved in species ranging from C. elegans to human and RJ/eRJ mediated healthy
proteostasis is dependent on the regulation of IIS/DAF-16, it is highly possible that
RJ/eRJ might also be beneficial for human consumption to prevent or slow down the
onset neurodegenerative diseases.
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CHAPTER SIX CHAPTER SIX: FUTURE DIRECTION
In previous chapters, our findings indicated that Royal Jelly (RJ/eRJ)
supplementation extended C. elegans lifespan, increased their stress tolerance, and
protected against Aβ toxicity in AD worms. Intriguingly, this anti-aging effect acted
through increasing the transcriptional activity of DAF-16 and, in turn, improving the
healthy proteostasis in C. elegans. To this end, our studies not only revealed the
molecular mechanism underlying RJ/eRJ mediated beneficial effects but also
underscored the essential function of Insulin Signaling Pathway (IIS) and DAF-16 under
aging and disease conditions.
It is well known that DAF-16/FOXO, a highly conserved forkhead transcriptional
factor from C. elegans to mammals, is tightly regulated by post-translational
modifications (PTMs) and protein-protein interaction with its co-factors[214]. Noticeably,
DAF-16/FOXO plays a very important role in cell proliferation, energy metabolism, and
stress response. Additionally, DAF-16/FOXO supports the survival of organisms under
low glucose and fasting conditions, and protects cells from stress-induced cellular
damages. However, the dysregulation of DAF-16/FOXO results in age-related disorders,
such as cancer, diabetes and neurodegenerative diseases[35]. Based on DAF-16/FOXO’s
important anti-aging functions, it is worth studying how the regulatory specificity of
DAF-16/FOXO is determined in cells under normal and aging conditions.
Numerous studies demonstrated that FOXO transcriptional factors are regulated
by certain external factors, including nutrients, environmental stressors, and cytokines.
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These external stimuli could induce the post translational modifications of FOXO to alter
its structural and functional properties, which in turn regulate the subcellular location and
transactivity of FOXOs. To date, phosphorylation, acetylation and ubiquitylation are
best-studied PTMs of FOXOs.
It has been proposed that FOXO phosphorylation is often induced by signaling
pathways and cellular stresses. For instance, under the activation of IIS pathway,
AKT/PKB phosphorylates FOXO and, in turn, sequesters FOXO in the cytosol rather
than assists their nucleus translocation. In contrast, under oxidative stress, the c-Jun Nterminal kinase (JNK) pathway phosphorylates FOXO and thereby increases its
transactivity to protect cells from oxidative damage. Taken together, the different sites of
FOXO phosphorylation result in opposite functions in cells, either activation or
inactivation of FOXO, which highlights the link between precise PTMs and specific
functions[45].
In addition to phosphorylation, another frequently observed PTM of FOXO is
acetylation. Under the oxidative stress, FOXO can bind to several histone
acetyltransferanse (HATs) , which might reduce the DNA binding capacity of FOXO and
thereby decrease its transactivity. However, this negative effect can result in reduced
HDACs (histone deacetylases). It is reported that in mammalian models, FOXOs are
acetylated by HATs, such as P300/CBP and CBP-associated factor (P/CAF) and
deacetylated by SIRT1[215].
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In addition to phosphorylation and acetylation, ubiquitylation also modulates
FOXO’s activity. Several studies have described that polyubiquitylation leads to the
proteasomal degradation of FOXOs, whereas monoubiquitylation strongly increases the
transcriptional activity of FOXOs. In addition to these three PTMs, methylation and
glycosylation also regulate FOXO’s activity. In our research, RJ/eRJ significantly upregulated the activity of DAF-16, but further experiments are needed to be done to
investigate which types of DAF-16’s PTMs are triggered in RJ/eRJ supplementation
under normal and disease conditions[216].
Furthermore, as well as PTMs, several co-factors (binding partners) also modulate
FOXO’s activity and function. For instance, co-factor 14-3-3 could bind and sequester
DAF-16 in the cytosol under the activation of IIS pathway, which represses the DAF-16’s
nucleus translocation. However, under heat shock stress, 14-3-3 functions as a bridging
protein to promote the physiological interaction of DAF-16 and SIR-2.1, which in turn
increases the transactivity of DAF-16 in the C. elegans model. Another important DAF16 co-factor is HCF-1, which also physiologically interacts with DAF-16 and represses
its activity. Specifically, in our research we found that SIR-2.1, 14-3-3 and HCF-1 were
required to modulate DAF-16’s activity under RJ/eRJ supplementation. Moreover,
besides of these three co-factors, other DAF-16 binding partners might be also involved
in RJ/eRJ mediated anti-aging effect, such as BAR-1, SMK-1 and RLE-1[159]. Further
experiments are needed to be carried out to better understand the detailed molecular
mechanism underlying this intricate protein-protein interaction[48, 49, 65].
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Overall, RJ/eRJ supplementation provides us a good nutrigenetic model to further
investigate the precise mechanism of how DAF-16/FOXO is regulated under aging and
disease conditions.
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Figure 6.1 Summary of post-translational modifications on the various FoxO
isoforms. (Horst et al., 2007)
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In order to approach our goal, several experiments are needed to conduct in the
future. Firstly, we wondered what PTMs of DAF-16 are triggered under RJ/eRJ
supplementation. The wildtype N2 and AD worms will be supplemented with RJ/eRJ for
several days, and then the purified DAF-16 proteins will be analyzed by MS-Spec
methods to analyze their PTM pattern. After comparing the differences between RJ/eRJ
treated worms and non-treated controls, we will determine the types of PTMs on DAF-16
triggered by RJ/eRJ supplementation. Noticeably, this unique pattern on DAF-16 could
be utilized as an indicator to screen efficient anti-AD drugs. As well as we know the
RJ/eRJ mediated specific PTMs of DAF-16, we will further investigate the proteinprotein interaction between DAF-16 and its binding partners, which will help us to better
understand how the regulatory specificity of DAF-16 is determined in healthy and aging
cells.
In conclusion, our findings revealed the molecular mechanism of RJ/eRJ’s antiaging effect, and underscored the link between an improving proteostasis and a healthy
aging. Moreover, we highlight that IIS/DAF-16 plays a key role in pro-longevity, stress
resistance and age-related disease prevention.
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